Materials Advances



View Article Online

Prof. Dwyer has more than 20

years clinical experience in the

diagnosis and management of

renal-related disease, including

acute and chronic kidney injury,

refractory hypertension and renal

transplantation. Her research

interests focus on purinergic signalling, specifically the role of

CD39 and adenosine signalling in

health and disease. She has

developed small animal models to examine acute and chronic

ischaemic induced kidney injury,

REVIEW



Cite this: *Mater. Adv.*, 2021, 2, 7210

Received 17th September 2021, Accepted 17th October 2021

DOI: 10.1039/d1ma00859e

rsc.li/materials-advances

Blood apheresis technologies – a critical review on challenges towards efficient blood separation and treatment

Christine Jurene O. Bacal, (1)*^{ab} James W. Maina, (1)^b Harshal H. Nandurkar,^c Maryam Khaleel, (1)^{def} Rosanne Guijt, (1)^g Yung Chang, (1)^h Karen M. Dwyer^a and Ludovic F. Dumée (1)*^{def}

Blood apheresis technologies are crucial during blood donation and toxin removal. Current purification methods such as leukocytapheresis, erythrocytapheresis, thrombocytapheresis and plasmapheresis primarily rely on centrifugation and membrane filtration to separate blood components. Although established and scaled-up, challenges related to the selectivity and long-term impact of these techniques on blood cells and their constituents remain. Shear generated during extraction may stress blood cells leading to cell damage and initiate the complement cascade causing platelet activation or triggering inflammatory responses. Emerging technologies, including microfluidics and selective adsorption present viable alternatives supporting more selective extraction pathways but extensively rely on novel manufacturing or material developments. This review critically assesses recent progress across apheresis technologies relating to advances in surface science and materials engineering to address operating challenges towards selective removal or extraction of blood components in traditional apheresis technologies such as centrifugation and membrane filtration.

^a Deakin University, Geelong, School of Medicine, Waurn Ponds, 3216, Victoria, Australia. E-mail: cbacal@deakin.edu.au

^b Deakin University, Geelong, Institute for Frontier Materials, Waurn Ponds, 3216, Victoria, Australia

^c Alfred Health, Australian Centre for Blood Diseases, Monash University, Melbourne, 3004, Victoria, Australia

^d Department of Chemical Engineering, Khalifa University, Abu Dhabi, United Arab Emirates. E-mail: ludovic.dumee@ku.ac.ae

^e Center for Membrane and Advanced Water Technology, Khalifa University, Abu Dhabi, United Arab Emirates

^fResearch and Innovation Center on CO₂ and Hydrogen, Khalifa University, Abu Dhabi, United Arab Emirates

^g Centre for Rural and Regional Futures, Deakin University, Geelong, VIC 3220, Australia

^h R&D Center for Membrane Technology and Department of Chemical Engineering, Chung Yuan Christian University, Chung-Li, 32023, Taiwan



Christine Jurene O. Bacal

Christine Jurene O. Bacal finished her undergraduate degree in Chemistry in the University of the Philippines – Diliman and took up her Masters in the same university. During her Masters, she specialized in bioprospecting of local fungal endophytes for carbohydrate-active enzymes (CAZys). Currently, she is a PhD candidate of both the School of Medicine (SoM) and the Institute for Frontier Materials (IFM) at Deakin University, Australia.

Her research is now focused on developing a more selective haemodialysis membrane for acetaminophen overdose patients.



Karen M. Dwyer

and renal, liver and islet transplant related injury. Prof. Dwyer also has an interest in clinical research project specifically surrounding the diabetes arising post transplantation.

1. Introduction

Blood is an essential biological fluid containing several blood cell types, such as red (RBCs), white (WBCs) blood cells and platelets, all contained in plasma as the liquid component enabling the transfer of the blood throughout the body.¹ Abnormalities in these blood components can lead to various blood diseases necessitating treatment known as apheresis.

Apheresis is an extracorporeal medical procedure that involves removal of blood components temporarily utilizing centrifugal force, size and structural differences of blood components and surface forces in microchannels as basis of separation.²⁻⁵ Apheresis has two types based on purpose therapeutic and diagnostic.⁶ In therapeutic apheresis, diseasecausing blood components were removed in critically ill patients.^{7,8} Therapeutic apheresis techniques are utilized to treat patients with multiple myeloma,⁹ thrombotic thrombocytopenic purpura (TTP) (formation of blood clots in small blood vessels),^{10,11} neurological diseases,¹² end-stage renal disease (ESRD)^{3,13} as well as drug toxicities.^{14,15} Meanwhile, diagnostic apheresis involves isolation of blood components for disease prognosis¹⁶ and is typically applied in cancer research.¹⁷ For instance, mononuclear cells (MNC) which are of low abundance (only $\sim 0.06\%$ of all blood cells), are often separated from the bloodstream using diagnostic apheresis techniques without the need of biopsy (a procedure that involves taking a tissue specimen from the patient for the purpose of diagnosing a disease).¹⁶

Apheresis procedures may also be classified based on the types of blood component to be extracted, and include erythrocytapheresis and leukapheresis for respectively RBC and WBC extraction, and thrombocytapheresis and plasmapheresis for the collection of platelets and blood plasma respectively.¹⁸ The apheresis procedure remains challenging due to the complexity of blood matrix, the variations in blood composition between donors¹⁹ and risks of inducing cell damage.²⁰ Apheresis techniques



Ludovic F. Dumée

Ludo is an Assistant Professor at Khalifa University, Abu Dhabi, United Arab Emirates. His work is focused on the development of advanced separation materials stemming from the properties of nanoscale materials. His team investigates routes to generate efficient separation membranes and catalysts from 1D and 2D nanomaterials toward the design of isoporous membranes for ultra-selective separation of cells, proteins, and pollutants.

He is active in developing innovative separation technologies with lower operating costs and footprint to support Circular Economy strategies. can affect cell integrity and biological function^{21,22} due to the shear stress experienced during the extraction processes. In addition, only a limited number of different components can be collected simultaneously within a single apheresis procedure due to long treatment times which can lead to significant risks of blood contamination caused by transfusion-transmitted pathogens such as HIV, hepatitis B and C virus, prions, to name a few.²³ The most mature and clinically implemented technologies enabling blood apheresis include centrifugation and membrane filtration.9 Progress in terms of equipment capabilities, separation material biocompatibility and performance has led to increased shelf-life, greater purity of the extracted components as well as more rapid processing of larger blood volumes.²⁴ Challenges related to platelet activation and biofouling during separation however still prevail, limiting the efficacy and utility of the procedure.²⁴ Hence, an assessment of the efficiency of existing and emerging apheresis techniques in relation to ultra-selective blood component extraction is required, while considering the cost-effectiveness in more mature technologies.¹² So far, limited studies described key performance characteristics of the existing apheresis technologies²⁵⁻²⁹ and few comprehensively benchmarked current practices to emerging and alternative technologies, such as microfluidic-based or sorbentbased apheresis.³⁰ The impact of materials used or the operating parameters on the removal efficiency are also seldomly discussed.³¹ An analysis of the key performance characteristics of each apheresis techniques is therefore required²⁷ and must be tailored to a specific disease indication.³²⁻³⁴

This review discusses current blood apheresis technologies as well as emerging solutions and materials to separate specific components from blood. A comprehensive overview on the gaps remaining across these technologies in terms of extraction rate, separation yield, throughput and potential effects on cells will be presented. The performance and efficiency of these technologies, for both therapeutic and diagnostic apheresis techniques, will be assessed considering the improvements on surface characteristics, percentage of haemolysis and thrombogenicity. Fresh perspectives for further improvement of the technologies in terms of design and operating procedures, and perspectives towards integration of more efficient and biocompatible materials will also be offered.

2. Centrifugal-based apheresis

Differential centrifugation is the method used to separate blood components from whole blood based on their densities upon increasing either applied centrifugal force, spinning duration or number of centrifugal cycles.² Plasma has the lowest density thus settles last, platelets and leukocytes have intermediate densities and erythrocytes have the highest density among the blood cell components hence settling first compared to other blood cells at the bottom of the tube (schematic diagram on Fig. 1a).² Centrifugal-based apheresis is applicable during blood transfusions and isolation of blood **Materials Advances**




Fig. 1 Centrifugal-based apheresis. (a) Density-driven separation. Blood components are separated depending on the applied centrifugal force, spinning duration and number of centrifugal cycles. Yellow background represents blood plasma. (b) Impact of centrifugal force on separated blood components during centrifugation.³⁶ Leukocyte- (L-PRF) and platelet-rich fibrin clot (A-PRF) centrifuged at 2700 rpm for 12 min (A) and platelet-rich fibrin clot centrifuged at 1500 rpm for 14 min (B) showed that yellow clot from A-PRF was not fully separated from the red blood cell part due to lower applied centrifugal force. (c) Impact of increasing centrifugal duration on separated blood components. Electron micrographs of fibrin scaffolds at $10\,000 \times$ magnification showed thicker and less dense filaments upon 20 min centrifugation than 40 and 60 min centrifugation.³⁷ (d) Effect of centrifugation duration on free haemoglobin concentration. Free haemoglobin concentration (g L⁻¹) measured for either 5 or 10 min showed the same result for control and centrifuged sample.²¹ (e) Impact of number of centrifugation cycles on microRNAs.³⁸ Higher concentration of serum was observed at second centrifugation than the first cycle. Lower detection rates for microRNAs were observed after second centrifugation.

cells²⁶ and is the most utilized apheresis technique since it is versatile, fast to prime and set-up.²⁷

The main challenge of using centrifugation-based apheresis is the occurrence of haemolysis, or rupture of blood cells, caused by shear stress introduced during spinning.³⁵ The extent of haemolysis is dependent on centrifugal operating conditions such as operating mode to be used, centrifugal force, spinning duration and number of centrifugal cycles and will be discussed in this section.

2.1. Operating modes

There are two operating modes in centrifugal-based apheresis, which can either be manual or automatic.² Manual centrifugation involves pelleting cells in a swinging bucket centrifuge and discarding the supernatant after the centrifugal process.³⁹ Meanwhile, automatic centrifugation involves following a series of pre-set protocols from the centrifuge, depending on application with minimal user intervention.³⁹ Sample recoveries for each operating mode are quantified and compared in the literature using the percentage (%) in recovery, the volume recovered or the number of cells present in the supernatant before and after centrifugation.⁴⁰ The separation efficiency is, however, a measurement of the amount of blood components extracted or collected within the shortest time possible without compromising the integrity of these components.^{25,26,41}

The operation mode must therefore be selected carefully based on the type of cells to be separated to ensure high yields. Overall, in separating blood components for component collection using centrifugation, the yield of the peripheral blood stem cells (PBSC) during leukapheresis should be 2×10^6 CD34 cells or 2×10^8 mononuclear cells (MNCS) per kg body weight of the recipient.⁴¹ Also, since packed red blood cells (PRBC) and platelet concentrates (PLTC) contain mostly leukocytes, the number of leukocytes must be $<1.2 \times 10^9$ if the entire buffy coat, corresponding to blood portion consisting mostly of leukocytes and platelets, is to be discarded.⁴¹

The impact of manual or automatic centrifugation on the absolute volume of red blood cells recovered was evaluated and it was observed that using manual centrifugation, $\sim 201 \pm$ 3 mL per blood unit from a starting volume of 240-300 mL per blood unit and centrifugal speed of $4200 \times g^{42}$ was recovered yielding a recovery range of 67-84%. When automatic centrifugation was applied, the absolute red blood cell mass volume recovered stood at \sim 214 \pm 0.6 mL per blood unit from a starting volume of 240-250 mL per blood unit⁴² giving a higher recovery range of 86-89%. The recoveries of leukocytes and CD34+, a glycoprotein marker of blood stem cells, were also evaluated with both manual and automatic modes. Interestingly, no significant change in WBC count per kg dose recovery (0.9 ± 0.07) was obtained whether manual and automatic centrifugation were used.43 There was also no significant change in the CD34+ count per kg dose recovery (0.9 ± 0.09) when comparing both operation modes⁴³ demonstrating the need to select techniques based on cost-effectiveness. In the same study that compared the recovery of WBCs and CD34+, the separation efficiency was also compared in terms of processing times. Although both centrifugal modes showed no significant differences in recoveries, the processing time for manual

centrifugation (35 min) was much longer than that of the automatic centrifugation (28 min) for the same treated blood volume.⁴³ Longer processing times also typically lead to platelet loss and clotting events^{25,44} thus this factor must also be considered aside from the cost.

The sample purity is also affected by the centrifugal operating mode. The application of manual centrifugation was found to lead to discrepancies in spin speeds while additional user manipulations may lead to large variations in the quality and purity of the separated blood component.45 Automatic centrifugation can produce separated blood components that are more uniform in composition since protocols are set based on the blood component to be separated with minimal user intervention. For instance, the percentage of haematocrit, corresponding to the ratio of red blood cells to whole blood, was compared for both manual and automatic modes of centrifugation. The measured % haematocrit in manual mode was 73 \pm 9% compared to 89 \pm 7% for the automatic mode, demonstrating that purer red blood cells may be extracted with the latter. The purity variations can be attributed to the fact that manual centrifugation might induce greater mechanical shear stress to the sample due to the longer operating times, which may lead to platelet activation.⁴⁶ The percentage of haemolysis, or blood cell lysis, corrected for haematocrit for both modes was evaluated and it was found that percentage of haemolysis was greater (0.7 ± 0.20) for manual centrifugation compared to automatic centrifugation (0.4 \pm 0.2).⁴² Automatic centrifugation is therefore currently recommended unless cost prohibitive or additional user intervention is needed.

2.2. Centrifugal force

Centrifugal force, described to be either revolutions per minute (rpm) or relative centrifugal force (rcf) – also known as "g-force" (×g), is the apparent force pulling a blood component of interest away from the centre of rotation, caused by the component's inertia.^{9,41} Characterization of mechanical properties of blood components is important in diagnosing haematological disorders and optimizing the design of cardiovascular implants and blood circulating devices with respect to blood damage.²¹ A study discussed the effect of centrifugation on the markers of mechanical damage and RBC membrane.²¹ An increase in the free haemoglobin yield from 61 mg L⁻¹ to 79 mg L⁻¹ could be attributed to haemolytic damage caused by the forces associated with centrifugation, even at 900 × g.

Leukocyte- and platelet-rich fibrin clots (L-PRF) were also separated due to its significance in oral and maxillofacial regenerative therapies *via* centrifugation.³⁶ It was observed that when centrifugal force applied increased from 1500 rpm to 2700 rpm for 14 and 12 min respectively, the separation between the clot and the red blood cell became more defined regardless of the blood volume used (10 mL for 1500 rpm and 9 mL for 2700 rpm) (Fig. 1b). Cell viability of adipocytes was observed when centrifuged from blood and it was discovered that there was no significant difference in the cell viability in the centrifuged adipocytes.⁴⁷ After eight accelerations up to 20 000 × g for 10 min, the viability remained at around 80-90%.47 An increase in the centrifugal force alone could not be equated to higher purity samples. The level of plateletrich plasma obtained was 3.2 times that of the concentration of WB baseline when a centrifugal force of $200 \times g$ was used in 5 mL WB for two spins, 10 min each.⁴⁸ Comparatively, a platelet concentration factor of 3.47 was obtained from an 8.5 mL processed WB when centrifugation was performed at both $130 \times g$ and $250 \times g$ for a period of 15 min when performing a two-spin centrifugation process.⁴⁹ The centrifugation of WB at 460 \times g for 8 min using only one centrifugation spin step led to a platelet concentration factor of 2.67 above baseline.⁵⁰ When around 5-6 L of blood were processed, effects of centrifugal force on the collection efficiency of mononuclear cells were evaluated using packing factor (PF).⁵¹ Packing factor is defined as the exertion of relatively high centrifugal force on the anticoagulated blood entering the spinning channel. Higher platelet drop per litre processed blood was recorded $(2.2 \pm 0.6\%)$ when PF 4.5 was used instead of PF 4.0 (2.6 \pm 0.5%). Reduced platelet loss ultimately led to reduced platelet contamination which improved the quality of the collected cellular component. However, the mechanism on how the decreased centrifugal force affected platelets are not discussed in this study. Hence, centrifugal force must be interlinked to other operating parameters to optimize recovery and purity.

2.3. Spinning duration

The spinning duration refers to the required duration for a centrifugal cycle to end, affecting sample recovery, separation efficiency, purity and characteristics of the extracted cells. Longer centrifugation durations slightly increased the platelet recovery and decreased WBC concentrations in the upper supernatant layer after a first spin step at $100 \times g$ for both 6 min (platelet = 72 \pm 3%; WBC = 27 \pm 11%) and 10 min (platelet = $79 \pm 8\%$; WBC = $9 \pm 4\%$) intervals.³¹ Better platelet separation efficiency was also obtained in another study (92%) by applying an acceleration of 1900 \times g for 5 min as compared to $1300 \times g$ for 10 min.⁵² For fibrin scaffolds, less compaction and thicker filaments were observed in electron micrographs when centrifugation duration used was 20 min rather than 40-60 min (Fig. 1c).³⁷ Morphological analysis for fibrin fibre showed that mean fibre diameter decreased after centrifugation from 20 to 60 min on both horizontal (from 358 \pm 79 to 205 ± 57 nm, *p* = 0.04) and vertical (from 311 ± 63 to 138 ± 35 nm, p = 0.037) orientation of the rotors used.

In another study however, there is no significant effect in the free haemoglobin (fHb) concentration when the spinning duration was decreased from 7 min ($0.07 \pm 0.04 \text{ g L}^{-1}$) to 5 min ($0.07 \pm 0.03 \text{ g L}^{-1}$) at both $3000 \times g$ centrifugal force.⁵³ The same finding was obtained for the free haemoglobin concentration obtained when centrifugal force used was lower at both $900 \times g$ at 5 and 10 min centrifugation (61 mg L⁻¹ for control and 79 mg L⁻¹ for centrifuged samples at both 5 and 10 min) (Fig. 1d)²¹ Although the difference in duration is small, an increase in fHb concentration however small, can have a significant effect if it is above analyte specific haemolysis cut-off.⁵³ The adverse effects to cells as associated with the spinning duration and centrifugal force was also explored and correlated to adenosine triphosphate (ATP) (organic compound that drives many metabolic processes in cells) release with haemolysis.³⁵ An increase in the concentration of ATP was observed (from 1.4–4.7 nM) as the centrifugation time increased from 1 to 5 min (Fig. 1c) while varying the applied centrifugal force from 900–16 000 × g.³⁵ The magnitude of ATP in the packed RBCs obtained using the parameters explored suggests that care must be taken when interpreting ATP transduction data in experiments that utilize centrifugation.

2.4. Number of spins

The number of spins pertains to the number of centrifugal cycles in a run. In most runs, centrifugation is repeated up to two cycles and increasing the number of spins can lead to a higher recovery of separated blood component. Processing of 3.5 mL of blood at $100 \times g$ for 10 min for the first spin and $400 \times g$ for 10 min for the second spin while withdrawing 2/3 of the remnant plasma to obtain platelets was performed.⁴⁰ Although a high platelet recovery of 70–80% was obtained, approximately 20% of the platelets remained adsorbed in the RBC pellet⁴⁰ after the second spin. Hence, a recorded 5-fold increase in platelet concentration⁴⁰ still requires optimization of the number of spins along with centrifugal force and spinning time to increase the yield and quality of the separated blood components.

The separation of other components found in blood, such as microRNAs, are critical since they serve as biomarkers for tumour diagnosis and prognosis.38 The content in representative microRNAs was found to decrease after a two-step centrifugation as compared to a single-step centrifugation. The cell count of miR-BART5, a type of microRNA from a virus involved in a variety of human tumours, in the blood plasma was 40 when a two-step centrifugation was applied compared to 33.5 for a single-step centrifugation process, suggesting that the number of viral microRNAs left in the blood decreased.³⁸ The total signal detection rate of microRNAs also decreased (15.3%) when a two-step centrifugation was applied compared to a single-step centrifugation (21.1%) (Fig. 1e).³⁸ For the evaluation of the purity of detected microRNAs, size distribution of the particles from exosomes - carrier of microRNAs with expected particle size of 30-150 nm,⁵⁴ were assessed by Dynamic Light Scattering (DLS). Particles with mean diameters of 63 nm present after a one-step centrifugation process were found to increase to 170 nm after a two-step centrifugation.³⁸ However, this two-step protocol did not demonstrate if the extracted microRNAs found after both the first and second steps were similar, and determination of the purity for these biomarkers is yet to be confirmed.

Platelet and leukocyte separation were evaluated after a single and two-step process and it was found that platelet concentration only increased by 1.5-fold for single-step compared to 4.7-fold for a two-step process. The leukocyte concentration factor also did not increase for the single-step process but was raised 1.4-fold after the two-step procedure.⁵⁵

2.5. Conclusions for centrifugal-based apheresis

Although centrifugation has been the most utilized and established method of separating blood components, intrinsic limitations persist. Centrifugation is labour-intensive and expensive, as the whole apheresis process involves elaborate sample handling and storage most especially in industries that supply blood products where high-capacity centrifuges are utilized.²⁰ Variations in separation time, non-reproducibility and low selectivity limit the practical use of traditional centrifugation separation technology.¹⁹ The main drawback is often related to strong mechanical shear stress induced on the cells, triggering platelet activation and causing haemolysis which can decrease the utility of the extracted blood component.41,56 Platelet activation primarily affects the quality of the recovered or extracted blood component by overwhelming the size of the component of interest. Consequently, more anticoagulants are required adding complexity with regards to potential long-term adverse effects including tendency to suffer from bleeding. This technique can also lead to platelet loss of up to 50% since platelets have a similar density as blood plasma and are therefore difficult to separate from the main blood matrix.^{25,44,57,58} Hence, despite the popularity of centrifugation, platelet activation and haemolysis underpin the search for alternative apheresis technologies.

3. Membrane-based apheresis

In membrane-based apheresis, blood components are separated based on their differences in size. Membranes are fabricated to generate pore sizes that will sieve the blood component of interest while retaining other relevant components (schematic diagram on Fig. 2a).³ The main application of membrane blood filtration is to remove uremic toxins and excess plasma proteins such as urea, creatinine, immunoglobulins, complement factors and lipoproteins in patients with end-stage renal disease (ERSD) or autoimmune disorders.³²⁻³⁴ It can also be used to filter leukocytes (leukodepletion) to avoid transfusion-related diseases.59 These applications led to the classification of membrane blood filters as leukodepletion filters, plasma separation membranes and haemodialysis membranes.^{3,60,61} The inherent propensity of the membranes to foul (biofouling),²⁶ corresponding to the formation of a cake-layer composed mostly of biological materials, onto the active part of the membrane however represents a major operating challenge.

Properties of the membrane materials can be modified at will to increase biocompatibility and to improve the selectivity and resistance to biofouling.^{27,57,62} Various surface modification techniques are employed such as (i) materials blending, in terms of polymer mixing to form composite materials *via* physical or noncovalent interaction, (ii) surface grafting, whereby a covalent attachment of functional groups on the membrane surface is performed, and (iii) surface coating, whereby a layer covering the membrane surface is added to enhance biocompatibility.^{63–65} Hence, in this section, potential solutions to address technological gaps in membrane-based apheresis will be discussed including surface modification of




Fig. 2 Membrane-based apheresis. (a) Size-driven separation. Smallersized blood solutes such as electrolytes and globulins (plasma proteins) pass through the membrane sieves whereas larger blood cells such as the erythrocytes, leukocytes and platelets go along the direction of the blood flow. (b) Example of surface modification *via* coating. Poly(propylene) (PP) membranes were coated with a copolymer (poly(glycidyl methacrylate)*co*-sulfobetaine methacrylate) (poly(GMA-*co*-SBMA) with zwitterionic properties to minimize membrane fouling.⁶⁶ (c) Example of surface modification *via* grafting. Cellulose membranes were modified by grafting zwitterionic polymers *via* surface-initiated atom transfer radical polymerization (ATRP).⁶⁷ (d) Example of surface modification *via* blending. A block copolymer of poly(lactic acid) (PLA)/poly(hydroxyethylmethacrylate) (PHEMA) was blended with the base material which is poly(lactic acid) to form a more biocompatible membrane.⁶⁸

the common materials used in membrane fabrication for enhanced biocompatibility. Membrane performance before and after surface modification will be evaluated to determine the suitable techniques that can be applied for improved removal efficiencies.

3.1. Membranes for leukodepletion

Leukodepletion filters extract white blood cells for the purpose of preparing red blood cells (RBCs) and platelets or removing micro-aggregates, clots, and particle debris from stored or salvaged blood components.⁶⁰ The mechanisms of leukocyte removal could either be driven through cell sieving, based on size or molecular weight cut-off, or cell adhesion, based on the bio-chemical affinity between the membrane and WBCs.⁶⁰ In the 1980s, Asahi and Pall successively proposed non-woven fabric systems for reducing white blood cells.^{59,69–71} Surface grafting of leukocyte filters with positively charged polymers was found to enhance the adsorption of electronegatively charged leukocytes.⁷² In the past 30 years, this concept has been widely used in the development of membrane systems for leukocyte removal processes.⁶⁹ The currently available commercial leukocyte filters which fulfil the criteria of both the European Council (EC) and the American Association of Blood Banks (AABB) for leukoreduced blood components, as well as newly developed leukocyte filters for enhanced leukodepletion are summarized in Table 1.⁷³

Current commercial leukodepletion filters have removal efficiencies of up to 99% and blood components recovered are at around 90% which satisfies the criteria set by the EC and AABB (Table 1). Membrane surface modification played a key role in enhancing the recovery of leukoreduced blood component yields when these filters are used during leukocyte filtration. Blending, coating or grafting of membrane surfaces affects the surface wettability and charge, thus supporting altered solute/matrix interactions, while also dictating the compatibility of the materials.⁵⁹ Leukocytes were shown to exhibit a greater adherence to wettable surfaces as modelled by observing changes in the free energy of solid surfaces⁷⁴ and more hydrophilic filters, characterized by low contact angles ($<90^{\circ}$),⁷⁵ are beneficial to increase the leukocyte removal efficiency.

3.1.1. Poly(ester) leukodepletion filters. Leukodepletion filters are typically made out of nonwoven polyester fibres since it can easily be processed by melt-blowing (one-step fibre fabrication process where fibres are extruded from nozzles by hot, high-velocity air)⁵⁹ without compromising its effectivity to remove leukocytes.^{69,76-79} Polyester is a hydrophobic material therefore surface modification of polyester filters can greatly improve leukocyte depletion efficiency. Also polyester has higher surface energy than other materials for leukocyte filtration like poly(urethane) which makes it more attractive as base materials for leukocyte filters.⁷¹ Commercial nonwoven polyester fibres for leukodepletion of whole blood can recover up to 90% of erythrocytes while filtering up to 99.3% of leukocytes (Table 1, entry 1).^{69,76-78} Aside from erythrocytes, platelet recovery is also a concern during leukofiltration to avoid thrombocytopenia (which may lead to bleeding). Phosphorylcholine (PC), a major phospholipid head group commonly found in outer leaflet of biomembranes, is gaining attention due to its haemocompatibility caused by its zwitterionic structure (hydrophobic head with a hydrophilic tail).⁸⁰ In recent years, a new concept of material design has been proposed that can specifically capture white blood cells, called a zwitterionic bias system.⁸¹ A material must have a combination of zwitterionic groups and charged groups. In an appropriate ratio, it can achieve low platelet activation and a high percentage of leukocyte removal rate. The system was commercialized in 2016 by the start-up company PuriBlood, and clinical testing was introduced.82 It has now passed the US FDA and EU CE certification, becoming a new generation of leukocyte filters that can be used to efficiently reduce white blood cells. The internal processing of 500 mL blood achieves a 99.9% leukocyte removal in less than 10 min, making it the fastest filtration system.

In one study,⁸³ leukocyte depletion increased from around 55% in unmodified membrane to around 90% upon coating the

Table 1 Materials used for leukocyte filtration and surface modification techniques applied for enhanced separation

Entry	Material	Surface- modified?	Type of surface modification mainly applied	Blood component recovered	Leukocyte depletion	Recovery
1	Nonwoven polyester fibres ^{69,76–78}	Yes	ND^{a}	Erythrocytes	Up to 99.3%	>90%
2	Nonwoven polyester fibres ^{69,79,83}	Yes	Coating with phosphorylcholine- containing polymers	Platelets	>99%	93%
3	Microporous	Yes	Coating with poly(ethylene imine)	Erythrocytes	Up to 99.6%	>90%
	poly(urethane) ^{69,70,77,78}		0 1 50 5	Platelets	>90%	>90%
4	Microporous polyurethane ⁸⁵	Yes	Grafting with Na ₂ SO ₃ , H ₂ SO ₄ , glycine, ammonia, NH(C ₂ H ₅) ₂	Erythrocytes	\sim 13% permeation ratio of erythrocytes	<5%
			and NH ₂ C ₂ H ₄ OH	Platelets	\sim 25% permeation ratio of platelets	<5%
				T-Cells	\sim 24% permeation ratio of T-cells	$\sim 20\%$
				B-Cells	∼10% permeation ratio of B-cells	$\sim \! 15\%$
				CD34+ cells	<1% permeation ratio of CD34+ cells	~70%
				Mononuclear cells	$\sim 2\%$ permeation ratio of mononuclear cells	<5%
5	Poly(propylene) membranes ⁸⁶	Yes	Grafting with poly(DMAEMA- co-PEGMA)	Erythrocytes	99.6%	98%
6	Poly(propylene) membranes ⁶⁶	Yes	Coating and crosslinking with poly(GMA- <i>co</i> -SBMA)	Erythrocytes	>99.9%	$\sim 100\%$
7	Poly(propylene) nonwovens ⁸⁷	Yes	Grafting of "LDV" peptidomimetics	Erythrocytes	\sim 3.71 log depletion	$\sim 100\%$
8	Melt-blown poly(butylene terephthalate) ¹⁹²	Yes	Grafting with polar groups (not disclosed)	Erythrocytes	99.03%	95.48%
9	Nonwoven poly(butylene) terephthalate ⁹⁰	Yes	Grafting of poly(vinyl pyrrolidone)	Erythrocytes	96%	92%
10	Nonwoven poly(butylene) terephthalate ⁹¹	Yes	Coating with hydroxyapatite	Erythrocytes	98.5%	99.5%
11	Electrospun poly(ethylene- <i>co</i> -vinyl alcohol) ⁹²	No	ND	Erythrocytes	Up to \sim 99%	>90%

Open Access Article. Published on 18 October 2021. Downloaded on 5/26/2025 6:03:26 AM.

polyester fibres with phosphorylcholine-containing polymers such as $MPC_{37}LMA_{63}$ (polymer consisting of 2-methacryloyloxyethylmethacrylate (MPC) and lauryl methacrylate (LMA)) (Table 1, entry 2). This result can be attributed to the reorientation of hydrophobic PC head towards the surface of the base material (polyester) minimizing interfacial energy upon blood contact.⁸⁴ As a proof of the reorientation phenomenon, the dynamic contact angle of membranes coated with $MPC_{37}LMA_{63}$ also showed that the initial contact angle was high at around 110° but after a brief immersion in water, the contact angle decreased to around 30° . Upon exposure to an aqueous environment, positively charged PC groups tend to reorient towards the surface minimizing the interaction of the polyester membrane with the blood during coating.

3.1.2. Poly(urethane) leukocyte filters. Other leukocyte filters are made from microporous poly(urethane) (PU) since PU is also a well-known biocompatible polymer while maintaining its hydrophobicity (Table 1, entries 3 and 4).^{69,70,77,78,85} Asymmetric poly(urethane) membrane filters with pore sizes decreasing from 65 μ m to 15 μ m in the direction of the blood flow led to a moderate removal of leukocytes (>80%) achieved at an operating blood flow rate of ~0.2 mL s⁻¹.⁷¹ The leukocytes were only moderately removed since white blood cells such as granulocytes and lymphocytes which comprise about 82% of leukocytes in the body, have a mean size smaller than 15 μ m.⁶⁹

Commercial filters have similar performance with nonwoven polyesters when coated with a hydrophilic polymer, poly(ethylene imine) (PEI).^{69,70,77,78} A stable coating with a complete coverage of 0.1 mg m⁻² based on ¹⁴C-labeled PEI mapping of the membrane surface showed that PEI-coated PU leukocyte filters increased the leukocyte depletion efficiency to >95% compared with the unmodified filters with efficiency of ~80%. PEI enhanced the performance of PU filters by introducing hydrophilic amine groups on the PU membrane surface. X-Ray photoelectron spectroscopy (XPS) results showed an increase in the nitrogen content from 2.4% in unmodified membranes to 3.8% after PEI coating, which verifies that the improved leukocyte removal efficiency is caused by incorporation of a stable PEI coating.

3.1.3. Poly(propylene) leukocyte filters. Poly(propylene) (PP) is also a commonly used material in leukocyte filters (Table 1, entries 5–7)^{66,86,87} because these highly-porous materials, like poly(sulfone), can be prepared through well-known and controlled processes such as phase inversion, cast film or melt extrusion.^{88,89} Like in other membrane materials, plasma proteins and other blood cells aggravate the tendency of PP membranes to foul reducing the removal efficiency of these filters. A study showed another positive influence of employing a zwitterionic co-polymer in improving the membrane performance and reducing fouling.⁶⁶ Here, coating PP fibres with poly(glycidyl methacrylate-*co*-sulfobetaine methacrylate) (poly-GMA-*co*-SBMA)

(Fig. 2b) presented a high reduction in adsorption of not only leukocytes but also fibrinogen, erythrocytes, thrombocytes and cells from whole blood as compared with the unmodified membranes. Poly-GMA-co-SBMA is immobilized using a crosslinker, ethylenediamine (EDA), and the results were compared before and after adding the crosslinker in the coating bath. The coating density of adding poly-GMA-co-SBMA alone reached to a maximum value of 0.12 mg cm⁻² but adding EDA along with the zwitterionic copolymer pushed the coating density to 0.25 mg cm^{-2} . This result shows a direct correlation with the water contact angle wherein membranes have a contact angle of 125° when poly-GMA-co-SBMA was added alone compared with the unmodified membrane with a contact angle of 135°. There was however limited difference until EDA was added pushing the contact angle to 0° given that the concentration of poly-GMA-co-SBMA was 1 mg mL⁻¹. The drastic change from being a highly hydrophobic to superhydrophilic polymer led to a leukocyte removal efficiency of >99% without altering the erythrocyte concentration in the permeate compared with unmodified membranes with only \sim 50% retention.

3.1.4. Poly(butylene terephthalate) leukocyte filters. A surfacegrafted commercial leukocyte filter non-woven poly(butylene terephthalate) (PBT-NW) fabric was found to improve the leukocyte retention and erythrocyte recovery (Table 2, entry 9)⁹⁰ by grafting with poly(vinyl pyrrolidone) (PVP) using oxygen plasma priming treatments. Upon the evaluation of the membrane surface wettability through the measurement of the critical wetting surface tension (CWST) parameter, CWST increased from 44.2 to >92.5 mN m⁻¹ upon plasma priming. CWST of haemocompatible materials were previously reported to require to be of at least 78 mN m^{-1} in order to see if liquid applied wetted the pores or remained as a droplet on the membrane surface.⁸³ The leukocyte retention and erythrocyte recovery were increased from ~85% to 96% and from ~83% to 92%, respectively, using these grafted PBT non-woven fabrics. Aside from grafting PVP, leukocyte filter performance was also improved upon addition of hydroxyapatite, deposited onto the surface of PBT nonwoven fibres.⁹¹ The water contact angles were measured for both pristine PBT-NW and HA-coated membranes leading to a decrease from 124° (pristine) to 100° (HA-coated) after deposition. The improved hydrophilicity generated by the HA addition increased the removal efficiency of leukocytes from $\sim 85\%$ to 98.5%, and that of erythrocytes from ~95% to 99.5%. A challenge remains related to the long-term stability of HA, and potential leaching of the loosely polymerized materials into the blood stream. The release of such additives could yield potential pathogenic effects when blood is returned to the body, which shall be carefully investigated in future studies.

3.1.5. Poly(ethylene-*co*-vinyl alcohol) leukocyte filters. Electrospun poly(ethylene-*co*-vinyl alcohol) membranes have the exceptional advantage of being spun using nontoxic solvent such as rubbing alcohol.⁹² These membranes are prepared with a range of nanofibre diameters, and it was reported that leukocyte adhesion was identified across the thickness of samples (Table 1, entry 11).⁹² A histological examination showed that the fibre diameters, ranging from 0.7 to 3.0 μ m, however played a significant role since very few cells were found to adhere

onto membrane materials made from 0.7 μm fibres, while a larger density of leukocytes was present across the membranes with larger fibres and thus pore size distributions.

3.2. Membranes for toxin removal

Aside from leukocytes with sizes ranging from $6-10 \mu m$,⁶⁹ other blood components such as plasma proteins and uremic toxins are removed to achieve haemostasis. Plasma separators are used for the purpose of collecting plasma proteins such as immunoglobulins, albumin and lipopolysaccharides, which are known precursors to endotoxins and cholesterols including low-density lipoprotein (LDL) and high-density lipoprotein (HDL) and to replace unhealthy blood plasma with a fresh and healthy one in patients with autoimmune diseases.9 Plasma components have pore sizes of >100 nm hence the pore size distribution range of membrane plasma separators is typically narrower and finer than that of leukodepletion filters, and in the microfiltration (MF) range of 0.2 to 0.8 µm.⁹³ Haemodialysis membranes, on the other hand, are primarily employed for the removal of low molecular weight uremic toxins (<500 Da) which could be of the size of <10 nm.^{94,95} Higher molecular weight toxins $>60\,000$ Da with a size range >10 nm but <100 nm are removed by haemofiltration membranes, the separation mechanism follows the principle of convection and not diffusion, as with haemodialyzers.^{3,96} Currently available membranes for toxin removal are presented in Tables 2 and 3.

Plasma separators and haemodialyzers could be made out of cellulose or synthetic polymers such as poly(sulfone), poly-(ethylene), poly(lactic acid), to name a few (Table 3). Like in leukodepletion filters, these materials can be modified through the previously specified techniques for a more efficient separation of plasma proteins and uremic toxins. The use of zwitterionic polymers,⁶⁷ vitamin E⁹⁷ and chitosan⁹⁸ are only some of the added materials developed for a more enhanced performance and haemocompatibility. Interestingly, the use of nanoparticles such as silicon dioxide,⁹⁹ ferric oxide¹⁰⁰ and multi-walled carbon nanotubes¹⁰¹ are also explored as anti-fouling agents.

3.2.1. Cellulosic membranes for toxin removal. Cellulose membranes (CM) have been frequently used in blood purification therapies since production cost is inexpensive and these membranes are relatively thin compared to others facilitating easier component transport¹⁰² (Table 2, entry 2). However, a membrane with too many hydrophilic groups may lead to leukopenia or reduced number of WBCs.¹⁰³ Meanwhile, as the degree of substitution from the hydrophilic to less hydrophilic moieties, as in cellulose acetate, increases, there is also a higher propensity for protein fouling.⁸⁰ Hence, surface-initiated atom transfer radical polymerization (ATRP) was used to graft zwitterionic polymers on the membrane surface to balance the number of hydrophilic and hydrophobic moieties in cellulose membranes.⁶⁷ Surface-initiated ATRP involves esterification of hydroxyl groups using the initiator, 2-bromoisobutyryl bromide (BIBB) to form initiator-functionalized cellulose membranes (CM-Br) (Fig. 2c). Then, CM-Br sheets will be reacted with copper(1) bromide (CuBr), zwitterionic monomer and 2,2'-bipyridine (BPY)

(2) Type of surface modification applied Sourcesproteins Biood side Dialysate side NTP* NTP* Urge* 10 Urge* 10 Stating with with with event series in statistic radical Urge* 10 Urge* 10 Biording with Stop Urge* Urge* 10 10 10 ND Urge* Urge* 10 10 10 ND Urge* Urge* 2500 ⁴ 200 200 ND Urge* Urge* 200 200 200 200 ND Urge* Urge* 200			•			Flow rate (mL min ⁻¹)	$L \min^{-1}$	Solute clearance
$ \begin{array}{lcl} \mbox{Tilled} \mbox{Cultures}^{(2),(2)} & No & NO \\ \mbox{Tilled} \mbox{Cultures}^{(2),(2),(2)} & Yo & NO \\ \mbox{Cultures}^{(2),(2),(2),(2)} & Yo & NO \\ \mbox{Cultures}^{(2),(2),(2),(2),(2)} & Yo & NO \\ \mbox{Cultures}^{(2),(2),(2),(2),(2)} & NO & NO \\ \mbox{Cultures}^{(2),(2),(2),(2),(2),(2),(2),(2),(2),(2),$	Entry	Material	Surface- modified?	Type of surface modification applied	Solutes/proteins removed	Blood side	Dialysate side	(mL min ^{_1}) or % removal efficiency
$ \begin{array}{c cccc} Colludore actance20 Yes bic durp with SiO2, the colludore tracenter ^{0.046-10} Yes bin Yes bit the colludore tracenter ^{0.046-10} Yes bit the colloce trace$	7 7	Unmodified cellulose ^{193–196} Cellulose ⁶⁷	No Yes	ND ^a Grafting with zwitterionic polymers <i>via</i> surface-initiated atom transfer radical polymerization (ATRP)	Urea ^b Plasma proteins	10 ND		105 $44\%^{c}$
$ \begin{array}{lccccc} Cellubose triaceate^{20,007-000} & NO & NO & OD & OD & OD & OD & OD & OD$	3	Cellulose acetate ⁹⁹	Yes	Blending with \hat{SO}_2	Urea	2500^d		99.7%
$ \begin{array}{lcl} \mbox{Polyation} & \mbox{ND} & \$	4	Cellulose triacetate ^{29,197–200}	No	ND	Urea	300	500	1%0 262–287
Polysphate No No Nosphate 300 500 Polystaffone) ^(m) Yes Blending with Fe,O, Vitamin B12 300 500 Polystaffone) ^(m) Yes Conting with vitamin E Conting with vitamin E 200 500 Polystaffone) ^(m) Yes Conting with vitamin E Conting with vitamin E 200 500 Polystaffone) ^(m) Yes Conting with vitamin E Conting with vitamin E 200 500 Polystaffone) ^(m) Yes Conting with vitamin E Conting with vitamin E 200 500 Polystaffone) ^(m) Yes No NO 200 500 500 Polystaffone) ^(m) Yes No NO 200 500 500 Polystaffone No NO NO 200 500 500 Polystaffone No NO 200 500 500 500 Polystaffone No NO NO NO 200 500 500 500					Creatinine	300	500	242-277
Polycation ND					Phosphate Vitamin B12	300 300	500 500	227–252 152–202
Polyfaulfone) ¹⁰ Yes Blending with Pe,O, Trainin B12 Creatinitie 300 500 <th< td=""><td>5</td><td>Poly(sulfone)^{201–203}</td><td>No</td><td>ND</td><td>Urea</td><td>300</td><td>500</td><td>228-261</td></th<>	5	Poly(sulfone) ^{201–203}	No	ND	Urea	300	500	228-261
Poly(sulfone) ¹⁰ Yes Bending with Rs,O, Conspare 300					Creatinine	300	500	200-231
$ \begin{array}{lcl} \mbox{Poly(aulfone)}^{100} & \mbox{Yes} & \mbox{Biending with Fe}O, & \mbox{Urem} & 15 & 375 \\ \mbox{Poly(aulfone)}^{12,105,120} & \mbox{Yes} & \mbox{Conting with vitamin E} & \mbox{Conting with vitamin E} & \mbox{Conting with vitamin E} & \mbox{Conting with Witamin E} & \mbox{Conting Witamin H1} & \mbox{Conting Witamin H1} & \mbox{Non-Nash} $					Pnospnate Vitamin B12	300	500	164-210 94-138
Poly(sulfone) ^{47,264,197} Yes Coating with vitamin E Visamin E12 100 15 75.5 Poly(sulfone) ^{14,2,66,197} No ND ND SM 000 10 20<	9	Poly(sulfone) ¹⁰⁰	Yes	Blending with Fe_2O_3	Urea	15	37.5	75.1%
Polyfauffonel ^{74,2,2,10} Yes Coating with vitamin B Total 100 <td></td> <td></td> <td>1</td> <td>-</td> <td>Lysozyme</td> <td>15</td> <td>37.5</td> <td>35.6%</td>			1	-	Lysozyme	15	37.5	35.6%
Poly(sulfone) ^{13,1,16,1,19} No ND Consumption of the constraint	~	Poly(sultone)	Yes	Coating with vitamin E	Vitamin B12 Creatinine	100	10	$\sim 100\%$
Poly(sulfone) ^{3,2,3,4} No ND ND ND Poly(ether sulfone) ^{11,2} Ves ND ND ND Poly(ether sulfone) ^{11,2} Ves Blending with a commercial Dipprotein B 40° Poly(ether sulfone) ^{11,2} Ves Blending with a commercial Creatinine 300 500 Poly(ether sulfone) ^{11,1} Ves Blending with a commercial Titzmin B12 300 500 Poly(ether sulfone) ^{11,1} Ves Blending with a commercial Titzmin B12 300 500 Poly(ether sulfone) ^{11,1} Ves Blending with a commercial Titzmin B12 300 500 Poly(ether sulfone) ^{11,1} Ves Blending with a commercial Titzmin B12 300 500 Poly(ether sulfone) ^{11,1} Ves Blending with multi-walled carbon Urea ND 125,5 50' Poly(ether sulfone) ^{10,1} Ves Blending with multi-walled carbon Urea ND 125,5 50' Poly(ether sulfone) ^{10,1} Ves Blending with multi-walled carbon December of 10' 125,5 50' Poly(ether sulfone) ^{10,1} Ves ND ND 125,5 50' Poly(ether sulfone) ^{10,1} Ves ND ND 125,5 50' Poly(ether sulfone)					Chymotrynsin	100	10	$\sim 100\%$
Poly(sulfone) ^{12,254} No ND ND Poly(sulfone) ^{12,244} No ND 1000000000000000000000000000000000000					BSA	100	10	$\sim 2\%$
Poly(ether sulfone) ^{145,165,197} No ND ND Poly(ether sulfone) ¹¹⁷ Yes Blending with a commercial Upoprotecin-B 40° Poly(ether sulfone) ¹¹⁷ Yes Blending with a commercial Upoprotecin-B 40° Poly(ether sulfone) ¹¹⁷ Yes Blending with a commercial Ureal 300 500 Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Ureal 300 500 Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Ureal 10' 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Ureal ND 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ³⁰³ No ND Ureal ND 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ³⁰³ No ND Teaction no 15-45 ⁶ Poly(ether sulfone) ³⁰⁴ No ND 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ³⁰⁵ NO ND 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ³⁰⁵ ND ND 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ³⁰⁵ ND ND 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ³⁰⁶ ND ND 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ³⁰⁶ ND	8	Poly(sulfone) ^{32,204}	No	ND	Albumin	40^e		100%
Poly(ether sulfone) ^{143,165,197} No ND Ipportation billing in the sulfone) ^{143,165,197} No ND Poly(ether sulfone) ¹¹⁷ Yes Blending with a commercial Ipportatione 300 500 Poly(ether sulfone) ¹¹¹ Yes Blending with a commercial Treatine 300 500 Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Creatine 10' 500 Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Dely(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Dely(ether sulfone) ¹⁰¹ 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ¹⁰³ No ND 125, ⁶ / ₇ 50 ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰³ No ND 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ¹⁰³ NO ND 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ¹⁰³ NO ND 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ¹⁰³ Yes Dely(ether sulfone) ¹⁰⁴ 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ¹⁰³ ND ND 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ¹⁰⁴ Yes Dely(ether sulfone) ¹⁰⁴ 125, ⁶ / ₇ 50 ⁶ Poly(ether sulfone) ¹⁰⁴ Yes					IgG	40^e		100%
Poly(ether sulfone) ^{145,145,145} No ND ND Upporternsh 40 Poly(ether sulfone) ¹¹⁷ Yes Blending with a commercial Upporternsh 40 500 Poly(ether sulfone) ¹¹⁷ Yes Blending with a commercial Hippuric acid 10' Poly(ether sulfone) ¹¹¹ Yes Blending with a commercial Hippuric acid 10' Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Urashine 10' Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Urashine 10' Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon ND 125, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes ND ND 125, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰³ No ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰⁴ ND ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰⁵ No ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰³ ND ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰⁴ ND ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰⁵ ND ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰⁶ ND ND 123, ⁶ 50 ⁶ Poly(ether sulfone					IgM	40°		100%
Polyfether sulfone) ¹¹⁷ Yes Blending with a commercial Creatinine 300 500 Polyfether sulfone) ¹¹⁷ Yes Blending with a commercial Creatinine 300 500 Polyfether sulfone) ¹¹¹ Yes Blending with a commercial Creatinine 300 500 Polyfether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Creatinine 10' 10' Polyfether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Creatinine 10' 125, ^g 50 ^g Polyfether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Creatinine ND 125, ^g 50 ^g Polyfether sulfone) ²⁰¹⁵ No ND ND 125, ^g 50 ^g Polyfether sulfone) ²⁰¹⁵ No ND 125, ^g 50 ^g Polyfether sulfone) ³⁰¹⁵ No ND 125, ^g 50 ^g Polyfether sulfone) ³⁰¹⁵ No ND 125, ^g 50 ^g Polyfether sulfone) ³⁰¹⁵ No ND 125, ^g 50 ^g Polyfethylene) ^{384,312,106} ND ND 125, ^g 50 ^g Polyfethylene) ^{384,312,106} ND ND 125, ^g 50 ^g Polyfethylene) ^{384,312,106} ND ND 125, ^g 50 ^g Polyfethylene) ^{384,312,106} Yes <	c	192-1-2-1-2-1-2-1-2-1-2-1-2-1-2-1-2-1-2-	M		Lipoprotein-B	40°	001	$\sim 96\%$
Poly(ether sulfone) ¹¹⁷ Yes Blending with a commercial co-polymer, SlipSkin ^w (SS) Blending with a commercial tippurt acid 10' 300 500 Poly(ether sulfone) ¹¹¹ Yes Blending with a commercial tippurt acid 10' 300 500 Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Use 00' 10' Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Use ND 125, ^g 50 ^g Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Use ND 125, ^g 50 ^g Poly(ether sulfone) ²⁰³ No ND ND 125, ^g 50 ^g Poly(ether sulfone) ²⁰³ No ND 125, ^g 50 ^g Poly(ether sulfone) ²⁰³ No ND 125, ^g 50 ^g Poly(ether sulfone) ²⁰³ NO ND 125, ^g 50 ^g Poly(ether sulfone) ²⁰⁴ NO ND 125, ^g 50 ^g Poly(ether sulfone) ²⁰⁵ NO ND 125, ^g 50 ^g Poly(ether sulfone) ²⁰⁵ NO ND 125, ^g 50 ^g Poly(ether sulfone) ²⁰⁵ NO ND 125, ^g 50 ^g Poly(ether sulfone) ²⁰⁵ NO ND 125, ^g 50 ^g Poly(ether sulfone) ²⁰⁵ Yes Coating wit	'n	Loid enter satione)	INO		Oreatining	000	200	243-243 760 776
Poly(ether sulfone) ¹¹⁷ Yes Blending with a conmercial copolymer, SipSkin ^w (SS) Blending with a conmercial copolymer, SipSkin ^w (SS) Doly(ether sulfone) ¹¹¹ Yes Blending with a conmercial mdoxyl sulfate 000 500 Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Creatinine 10' Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Creatine 10' Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Creatine 10' Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Urea ND 125, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Urea ND 125, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes ND ND 125, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes ND 125, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes Coating with etholon 15-45 ⁶ Poly(ethylene) ^{38,80,3,206} Yes Coating with etholon 15-45 ⁶ Poly(ethylene) ^{38,80,4,100} ND ND 125, ⁶ 50 ⁶ Poly(ethylene) ^{38,80,4,100} ND ND 125, ⁶ 50 ⁶ Poly(ethylene) ^{38,80,4,100} ND ND 15-45 ⁶ Poly(ethylene) ^{38,}					Dhoenhote	300	500 500	272-802
Poly(ether sulfone) ¹¹⁷ Yes Blending with a commercial co-polymer, SlipSkin ¹⁴ (SS) Teratinic for an over a composition of the sulform of the sulfone) Total co-polymer, SlipSkin ¹⁴ (SS) Hippuric acid for a for body sulfate for body sulfate for a for body sulfate for body sulfate for body sufficience for a f					Filospilate Vitamin D17	300	200	100-106
Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Hippuric acid 10' Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Ures ND 125, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Ures ND 125, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Ures ND 125, ⁵ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Ures ND 125, ⁵ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes ND ND ND ND 125, ⁵ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes ND ND ND ND 125, ⁵ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes ND ND ND ND 125, ⁵ 50 ⁶ Poly(ether sulfone) ¹⁰² Yes ND ND ND ND 125, ⁵ 50 ⁶ Poly(ether sulfone) ¹⁰³ Yes ND ND ND ND 15-45 ⁶ Poly(ether sulfone) ¹⁰³ Yes Coating with ethylene vinyl Total cholescenol 15-45 ⁶	10	Polv(ether sulfone) ¹¹⁷	Yes	Blendino with a commercial	Vitanun B12 Creatinine	300 10 ⁶	000	$\sim 89\%$
Poly(ether sulfone) ¹¹¹ Yes Blending with multi-walled carbon Dives ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Drea ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Drea ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ¹⁰¹ Yes Blending with multi-walled carbon Dives ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ²⁰³ No ND ND 123, ⁶ 50 ⁶ ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ²⁰³ No ND ND 123, ⁶ 50 ⁶ ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ²⁰³ No ND ND 123, ⁶ 50 ⁶ ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ²⁰³ No ND ND 123, ⁶ 50 ⁶ ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ²⁰³ No ND ND 123, ⁶ 50 ⁶ ND 123, ⁶ 50 ⁶ Poly(ether sulfone) ²⁰³ No ND ND 123, ⁶ 50 ⁶ 15, ⁴⁵ Poly(ether sulfone) ²⁰⁴ ND ND ND 12, ⁴⁵ 15, ⁴⁵ <td>77</td> <td>t ord carrent samoure)</td> <td>100</td> <td>co-nolymer SlinSkin^{III} (SS)</td> <td>Hinniric acid</td> <td>10</td> <td></td> <td>~ 50%</td>	77	t ord carrent samoure)	100	co-nolymer SlinSkin ^{III} (SS)	Hinniric acid	10		~ 50%
$ \begin{array}{llllllllllllllllllllllllllllllllllll$					Indoxyl sulfate	10		$\sim 100\%$
Poly(ether sulfone)^{1.1}YesBlending with multi-walled carbonUreaND 125_{1}^{5} 50°nanotube (MWCNT) andCreatinineND 125_{1}^{5} 50°Poly(ether sulfone)^{101}YesBlending with multi-walled carbonND 125_{1}^{5} 50°Poly(ether sulfone)^{205}NoND 125_{1}^{5} 50° ND 125_{1}^{5} 50°Poly(ether sulfone)^{205}NoND 125_{1}^{5} 50° ND 125_{1}^{5} 50°Poly(ether sulfone)^{205}NoND ND 125_{1}^{5} 50°Poly(ether sulfone)^{205}NoND 125_{1}^{5} 50° 15_{1}^{5} 50°Poly(ether sulfone)^{205}NoND 125_{1}^{5} 50° 15_{1}^{5} 50°Poly(ethylene)^{36,93,206}YesCoating with ethylene vinyl 15_{1}^{5} 70° 15_{1}^{5} 45°Poly(ethylene)^{36,93,206}YesCoating with ethylene vinyl 15_{1}^{5} 60° 15_{1}^{6} 60°Poly(ethylene)^{36,93,206}YesCoating with ethylene vinyl 15_{1}^{6} 60° 16_{1}^{6} 50°Poly(ethylene)^{36,93,206}YesCoating with ethylene vinyl 16_{1}^{6} 60° 16_{1}^{6} 50°Poly(ethylene)^{36,93,206}YesCoating with ethy					BSA	10^{\prime}	5	1.83-Fold increase
Poly(ether sulfone)^{101}YesBandube (MWCNT) and Doly(rinyl pyrrolidone)CreatinineNU125,6 50°Poly(ether sulfone)^{101}YesBlending with multi-walled carbonBSAND125,6 50°Poly(ether sulfone)^{205}NoNDMD125,6 50°Poly(ether sulfone)^{205}NoNDND125,6 50°Poly(ether sulfone)^{305}NoNDND125,6 50°Poly(ether sulfone)^{305}NoNDND15-45°Poly(ethylene)^{58,33,206}YesCoating with ethylene vinyl15-45°Poly(ethylene)^{58,33,206}YesCoating with ethylene vinyl15-45°Poly(ethylene)^{58,33,206}YesCoating with ethylene vinyl15-45°Poly(ethylene)^{58,33,206}YesCoating with ethylene vinyl15-45°Poly(ethylene)^{58,33,206}YesCoating with ethylene vinyl16-50°Poly(ethylene)^{58,33,206}YesCoating with ethylene vinyl<	11	Poly(ether sulfone) ¹¹¹	Yes	Blending with multi-walled carbon	Urea	Q ;	$125,^{s} 50^{s}$	56.3%
Poly(ether sulfone)^{101}YesBlending with multi-walled carbon nanotube (MWCNT) grafted-poly(citric) acidLysosyme LysosymeNDNDPoly(ether sulfone)^{205}NoNDNDINCNT) grafted-poly(citric) acid15-45°Poly(ether sulfone)^{36,33,206}NoNDNDINF- α 15-45°Poly(ethylene)^{58,33,206}YesCoating with ethylene vinyl15-45°Fibrinogen15-45°Poly(ethylene)^{58,33,206}YesCoating with ethylene vinyl15-45°Apolipoprotein B15-45°Poly(ethylene)^{58,33,206}YesCoating with ethylene vinyl70tal protein15-45°Poly(ethylene)^{58,33,206}YesCoating with ethylene vinyl70tal protein216-50°Poly(ethylene)^{58,33,206}YesYesCoating with ethylene vinyl216-50°Poly(ethylene)^{58,33,206}YesYes216-50°216-50°Poly(ethylene)^{58,33,206}Yes216-50°216-50°Poly(ethylene)^{58,33,206}Yes216-50°216-50°				nanotube (MWCNT) and	Creatinine		125,° 50° 105 Å 50°	55.1% 27.002
Poly(ether sulfone)^{205}NoNDnanotube (MWCNT) grafted-poly(citric) acid LipopolysaccharidesLipopolysaccharides15-45° 15-45°Poly(ether sulfone)^{38,93,206}YesCoating with ethylene vinylLipopolysaccharides15-45° 15-45°Poly(ethylene)^{38,93,206}YesCoating with ethylene vinylAlbumin $<16-50°$ 15dPoly(ethylene)^{58,93,206}YesCoating with ethylene vinylAlbumin $<16-50°$ 15dPoly(ethylene)^{58,93,206}YesCoating with ethylene vinylAlbumin $<16-50°$ 15dPoly(ethylene)^{58,93,206}YesCoating with ethylene vinylAlbumin $<16-50°$ 15dPoly(ethylene)^{58,93,206}YesCoating with ethylene vinylAlbumin $<16-50°$ 15d	12.	Polv(ether sulfone) ¹⁰¹	Yes	poly(viiityi pyiroituoiie) Blendino with multi-walled carbon	Lysuzyine BSA		ND ND	27.3% 63.5%
Poly(ether sulfone)205NoNDLipopolysaccharides15-45°TNF-a15-45°TNF-a15-45°Total choice15-45°Total choiceFibrinogen15-45°Total choiceTotal choice15-45°Apolipoprotein BPoly(ethylene)58,93,206YesCoating with ethylene vinylAlbuminCoating with ethylene vinylAlbumin<16-50°	1	toria pariotical		nanotube (MWCNT) grafted-poly(citric) acid			2	
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	13	Poly(ether sulfone) ²⁰⁵	No	ND	Lipopolysaccharides	$15-45^e$		50%
Poly(ethylene) ^{58,93,206} Yes Coating with ethylene vinyl 15-45 ⁶ Fibrinogen 15-45 ⁶ Poly(ethylene) ^{58,93,206} Yes Coating with ethylene vinyl Ribrinogen 15-45 ⁶ Apolipoprotein B 15-45 ⁶ Apolipoprotein B 15-45 ⁶ Apolipoprotein B 15-45 ⁶ Apolipoprotein B 16-50 ⁶ IgG <16-50 ⁶ IgM <16-50 ⁶ IgM <16-50 ⁶					$1NF-\alpha$	$15-45^e$		75%
Poly(ethylene) ^{58,93,206} Yes Coating with ethylene vinyl Total cholesterol 15-45 ^e Poly(ethylene) ^{58,93,206} Yes Coating with ethylene vinyl Apolipoprotein B 15-45 ^e Poly(ethylene) ^{58,93,206} Yes Coating with ethylene vinyl Apolipoprotein B 15-45 ^e Rolify(ethylene) ^{58,93,206} Yes Coating with ethylene vinyl Apolipoprotein B 15-45 ^e Rolify(ethylene) ^{58,93,206} Yes Coating with ethylene vinyl Apolipoprotein B 15-45 ^e Rolify(ethylene) ^{58,93,206} Yes Coating with ethylene vinyl Albumin <16-50 ^e Rolify(ethylene) ^{58,93,206} IgM <16-50 ^e <16-50 ^e					C-Reactive protein	$15-45^e$		51%
Poly(ethylene)^{58,93,206}YesCoating with ethylene vinylIotal concesterol15-45°Rolifoptrotein $15-45°$ Apolipoprotein $15-45°$ Apolipoprotein $15-65°$ $16-50°$ $16-50°$ Internation $16-50°$ 126 $16-50°$ Internation $16-50°$ 126 $16-50°$ Internation $16-50°$ 126 $16-50°$ Internation 126 126 $16-50°$ Internation 126 126 126					Fibrinogen	$15-45^{e}$		51%
Poly(ethylene) 58,93,206 YesCoating with ethylene vinyl 70 Total protein $^{10-50}$ Roly(ethylene) 58,93,206 $^{16-506}$ $^{16-506}$ IgG $^{16-506}$ $^{16-506}$ $^{16-506}$ IgA $^{16-506}$ $^{16-506}$ $^{16-506}$ IgA $^{16-506}$ $^{16-506}$ $^{16-506}$					Total cholesterol	15-45 $15 - 45^{\circ}$		62% 500/5
roycurycur (1.5) coarus wur cuyer (1.5) Albumin $(1.6-50^{\circ})$ alcohol copolymer $(1.6-50^{\circ})$ $(1.6-50^{$	44	Dolvíathvlava)58,93,206	Vac	Contine with athylana vinyl	Apunpuprotern B Total arotain	لیا 16_50 ^و //16_50		0/6C
IgG $< 16-50^{6}$ IgA $< 16-50^{6}$ IgM $< 16-50^{6}$	ŗ	r ord(cardination)	1.03	alcohol copolymer	Albumin	$< 16-50^{e}$		97%
$<16-50^{e}$ $<16-50^{e}$				5	IgG	$<\!16-50^e$		93%
$<16-50^{e}$					IgA	$<\!16-50^{e}$		96%
					IgM	$<16-50^{e}$		95%

Open Access Article. Published on 18 October 2021. Downloaded on 5/26/2025 6:03:26 AM. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

(cc) BY-NC

7218 | Mater. Adv., 2021, 2, 7210-7236

Table 2 (continued)

Dutry		SUITACE-					(T
THUS	Material	modified?	Type of surface modification applied	sources/procents	Blood side	Dialysate side	(min min) of % removal efficiency
15	Poly(propylene) ²⁰⁷	Yes	Grafting with poly(2-methoxyethylacrylate) (nolv(MFA))	Total protein Albumin	20^e		100% $102%$
			((struct) (stord)	Total cholesterol	20^e		100%
				Fibrinogen	20^e		100%
16	Polv(lactic acid) ⁶⁸	Yes	Blending with graffed molv(lactic acid)- <i>block</i> -	Factor VII C	ON D	100.300	0.78
5			poly(2-hydroxyethyl methacrylate) (PLA-PHEMA)	Creatinine	QN	100, 300	0.74
			copolymers	Lysozyme	ND	100, 300	~ 0.70
				BSA	ND	100, 300	~ 0.35
17	Poly(lactic acid) ¹¹⁰	Yes	Grafting with heparin	Urea	200	500	79%
				Lysozyme	200	500	18%
0				BSA	200	500	<10%
18	Foly(annue)	ICS	biending with poly(vinyipytromaone) and	Urea	300	500	10/
			porklaryr eurer surrorrej	Dicaulille Disserves	000	200	140
				Vitemin D10	300	200	150
0	₽~1-7~208	Wee	متحصير الالمطيمية مسالمه طبلت مسالات		300	200	90 201 267
۲A	Poly(acry10111111e)	Ies	bienaing with somain methanyi sunonate	Orea	300	200	C07-197
					300	200	204-237
				Phosphate	300	500	1/2-20/
		:	1	Vitamin B12	300	500	106-143
20	Poly(methyl	No	ND	Urea .	200	500	184 - 192
	methacrylate) ^{103,137,209}			Creatinine	200	500	182–191
				Phosphate	200	500	155-179
				Vitamin B12	200	500	106 - 133
21	Poly(methyl methacrylate) ²¹⁰	No	ND	β_2 -Microglobulin	ND		$\sim 64\%$
22	Poly(methyl methacrylate) ²¹¹	No	ND	Total plasma	33^e		50
				Plasma proteins	33^e		100
				(β-lipoprotein, albumin,			
				IgG, IgM)			
23	Poly(urethane) ²¹²	Yes	Coating with 3,4-dichloro-5-hydroxy-	Human serum	ND	ND	64-70%
			2(5H)-furanone incorporated with poly(vinyl pyrrolidone) containing succinimidyl functional erouns	albumin (HSA)			
24	Nanoporous silicon ²¹³	No	ND	Creatinine	10	10	~ 109
				Urea	10	10	~ 150
				Phosphorus	10	10	~ 87
				β2-Microglobulin	10	10	~ 27

Review

ned on 18 October 2021. Downloaded on 5/26/2025 6:03:26 AM.	censed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licen
ed on 18 (censed un
ticle. Publishe	article is li
cess Arti	This
Open Acc	(cc) BY-NC

Jce.

Materials Advances

				Indicat	tors of t	Indicators of anti-thrombogenicity	mbogenic	city		Indicator of complement system activation	em activation
		Surface-		APTT (s)	s)	PT(s)		PRT (s)	(\$	Serum concentration ($\mu g \ mL^{-1}$)	(¹)
Entry	Entry Material	modified?	Type of surface modification applied	MU	М	MU	Μ	ΜŊ	М	UM	М
	Poly(sulfone) ¹²⁸	Yes	Grafting with acrylic acid and sulfonated hydroxypropyl chitosan	36.90	179	36.90 179 18.10	62.10	238	301	_p LN	NT
5	Poly(ether imide) ¹²⁹	Yes	Blending with graphene oxide/poly(vinyl pyrrolidone) nanocomposites	32	75	15	18	325	675	\sim 0.04 (C3a), \sim 0.0016 (C5a)	~0.028 (C3a), 0.0008 (C5a)
3	Poly(ether imide) ²¹⁴	Yes	Biending with functionalized multi-walled carbon nanotubes (f-MWCNT)/poly(vinyl pyrrolidone) composites	42.5	84	12.5	24.2	TN	NT	TN	, LN
4	Cuprophan ⁹⁸	Yes	Blending with chitosan interpenetrated with anionic polysaccharides	TN	TN	TN	NT	600	240-480	101.5 (iC3b)	63.2 (iC3b)
5	Cellulose triacetate ²¹⁵	No	ND CN	TN	TN	TN	NT	ΓN	NT	 (β-thyroglobulin) (7 (platelet factor 4) 	
9	Cellulose acetate ⁹⁹	Yes	Blending with SiO ₂	MU	\sim 55 $^\circ$	$\sim 55\%$ thrombosis $\sim 45\%$ thrombosis	bosis sosis			NT TN	

View Article Online

to form the zwitterionic polymer-grafted CM (Fig. 2c). Interestingly, by grafting one poly(phosphobetaine) and two poly(sulfobetaine) compounds using ATRP, the contact angle changed from ~47° in the unmodified membrane to ~34–20° in modified membranes. This result was due to the formation of a hydration layer *via* electrostatic interactions in addition to the hydrogen bonding.¹⁰⁴ Although it was shown that there was a decreased protein adsorption from 1.8 µg cm⁻² in pristine membranes to around 1 µg cm⁻² in modified membranes and reduced platelet adhesion based on the morphological analysis, the number of leukocytes was not measured in the pristine and modified membranes for this study. The problem on leukopenia is left unanswered and warrants further investigation.

Cellulose acetate (CA) membranes are also used in blood purification to address the problem with the number of -OH group in cellulose membranes that would lead to leukopenia (Table 2, entry 3).¹⁰³ Here, hydroxyls of the unmodified cellulose were substituted by acetate radicals to minimize hydrophilicity. Although CA membranes were linked to reduced complement activation due to the presence of negative charges on the surface that can adsorb the activated cationic complement peptide,¹⁰⁵ there are still a few concerns such as limited mechanical strength and shelf-life.^{106,107} To address these concerns, a novel method of covalently adding inorganic nanoparticles such as SiO₂ with mechanical and thermal stability properties to CA membranes was explored.⁹⁹ By combining the phase inversion and sol-gel techniques, a CA/SiO₂ monophasic hybrid membrane was formed. After optimizing the amount of silica added, it was found out that when 5 wt% silica was added to CA membrane, there was no significant change in contact angle but when 11 wt% and 18 wt% silica were added to the CA membrane respectively, the contact angle decreased from $\sim 40^{\circ}$ to around 14° and 22° respectively. The surface roughness will influence the hydrophilicity but when the average roughness of the hybrid membrane was obtained through atomic force microscopy, it was found that there is not much difference in the nano (1.0-2.5 nm) and the micro (6.0-7.3 nm) range for the CA membranes with 5, 11 and 18 wt% silica added thus surface roughness did not affect the hydrophilicity in this case. With regards to the anti-fouling ability, it was shown that urea is fully permeated with % rejection of $\sim 0.3\%$ for 11-18% silica-CA hybrid membranes from 2% in unmodified CA membranes whereas BSA is fully rejected in both modified and modified CA at 99% rejection. Hence, this membrane is selective in filtering urea and retaining BSA and plasma proteins with similar size which is highly desired during haemodialysis.

3.2.2. Synthetic membranes for toxin removal. Synthetic membranes were found to generally yield wider pore size distributions and greater biocompatibility than cellulosic membranes by slowing down leukocyte adhesion^{108,109} and therefore supporting faster filtration rates of >100 mL min⁻¹. As opposed to cellulosic membranes, synthetic polymeric membranes are hydrophobic and will certainly prevent leukocyte adhesion although these materials will promote protein adsorption and will foul easily. Hence, when separating proteins, it is better to have a hydrophilic additive for enhanced filtration flux.

3.2.2.1. Poly(sulfone) and poly(ether sulfone) membranes. Poly(sulfone) (PSf) and poly(ether sulfone) (PES) are the primary materials used in fabricating haemodialysis membranes and plasma filters however, high membrane hydrophobicity causing low removal efficiency of middle-molecular weight toxins such as β_2 -microglobulin is the current trade-off in using these membrane materials.¹⁰¹ The incorporation of metal oxides is also explored not only in cellulose acetate membranes⁹⁹ but also in synthetic polymers such as poly(sulfone). Iron(III) oxide (Fe_2O_3) is blended with poly(sulfone) membranes because aside from its hydrophilicity and nontoxicity, its nanostructure facilitates better water porosity at minimal operating pressure (Table 2, entry 6).¹⁰⁰ Although the exact mechanism of how it became a good liquid transport medium is not explained, true enough, PSf/Fe₂O₃ membranes exhibited more finger-like structures and thinner skin layer than PSf membrane alone. The pore size distribution also shifted to larger mean sizes due to the greater freedom in movement of Fe₂O₃ near the membranemoisture interface. The contact angle values decreased from 67° to 55° and water porosity increased from 43% to 67% leading to lesser human serum albumin (HSA) adsorption from 8.23 μ g cm⁻² to 6.68 μ g cm⁻² and higher BSA rejection from 91% to 98% in PSf/Fe2O3 membranes. The clearances for the relevant haemodialysis solutes - urea and lysozyme were 75.1% (from 52.3% urea clearance) and 35.6% respectively. Lysozyme clearance was better at 35.6% compared to other studies - 18% using heparin-immobilized poly(lactic acid) (PLA) membrane¹¹⁰ and 28% multi-walled carbon nanotube (MWCNT)-incorporated PES membrane.¹¹¹ Lysozyme has about the same molecular weight as the common middle-molecular weight β_2 -microglobulin (\sim 15 kDa) but the size of lysozyme is 9 nm in length and 1.8 nm in diameter.¹¹² β_2 -Microglobulin is <200 nm in length and ~10 nm wide.¹¹³ Better representation molecule for middle-molecular weight toxins must be considered in future studies.

Other surface modifications were also applied to PSf membranes such as coating PSf membranes with vitamin E to capture reactive oxygen species in blood that are activated during blood-membrane contact.⁹⁷ This is not the first time that vitamin E-coated PSf membranes were reported in the literature.^{114–116} However, this is the first study to demonstrate the mass-transfer characteristic of vitamin E-coated PSf membranes. Filtration experiments on aqueous test solutions of creatinine, vitamin B₁₂, chymotrypsin and albumin were done at flow rates of 100 mL min^{-1} on the blood side and 10 mL min⁻¹ on the dialysate side. Upon coating PSf membranes with α -tocopherol – the active form of vitamin E, it was discovered that there is no significant difference in the efficiency of small solute removal such as creatinine and vitamin B12 against the uncoated membranes ($\sim 100\%$). However, significant changes were observed when larger solutes such as chymotrypsin and albumin were filtered. The removal efficiency of chymotrypsin decreased from $\sim 86\%$ in uncoated membranes to $\sim 82\%$ in coated membranes during the first 30 min of filtration. Same changes were observed when albumin was filtered wherein the removal efficiency decreased to

 \sim 2% from \sim 4% during the first 30 min of filtration. Morphological analysis presented a wedge-shaped structure on the cross-section wherein large pores are filled with white drops that can be related to the successful coating of vitamin E. This result shows that addition of vitamin E influenced the mass transfer properties of the PSf membranes and can make the filter more selective towards small solutes and more discriminative towards middle to high molecular weight proteins such as albumin which is necessary for homeostasis.

Polymer blends were used to generate asymmetric membranes from poly(ether sulfone) (PES) and a co-polymer, SlipSkin[™] (SS) with randomly arranged monomeric moieties of hydrophilic NVP (N-vinylpyrrolidone) and hydrophobic BMA (N-butylmethacrylate) (Table 2, entry 10).¹¹⁷ Morphological analyses showed the presence of macrovoids in both PES-SS and PES-PVP membranes while no macrovoids were present across the PES-SS membranes. Enhanced long-term filtration fluxes for both PES-SS (1.3-fold increase) and PES-PVP (5-fold increase) were achieved compared to commercial F8HPS membranes, measured after 24 h of filtration. Interestingly, although the PES-SS membranes exhibited more macrovoids than the PES-PVP membranes, the relative flux for the PES-PVP was higher than that of the PES-SS (2.6-fold higher), which was attributed to leaching of PVP over time thus leading to unstable pore size and surface energy distributions within the materials. ATR-IR spectra confirmed this hypothesis where large variations in the intensity of the carbonyl peaks at \sim 1680–1700 cm⁻¹ for PES-PVP membranes were found between the reference sample and after 24 h of filtration. With regards to the anti-fouling ability of the PES-SS membranes, removal of both soluble (creatinine) and protein-bound uremic toxins (hippuric acid, HA and indoxyl sulfate, IS) were examined. The PES-SS membranes has $\sim 89\%$ better creatinine removal efficiency than commercially available low-flux F8HPS (Fresenius) fibres, which was linked to the presence of a hydrophilic NVP (N-vinylpyrrolidone) block within the SS polymer, into the selective layer and pore surface of the PES-SS hollow fibres. These NVP were anchored by the hydrophobic BMA (N-butylmethacrylate) block of the SS into the membrane polymer matrix leading to less interaction between the membrane and the soluble solute.^{118,119} Interestingly, there is a low removal efficiency for hippuric acid which is only $\sim 59\%$ which could be related to the fact that there is a higher protein interaction and adsorption of HA on the surface of the commercial membrane as compared to the PES-SS membrane. Also, HA binds to plasma proteins at a lower degree ($\sim 30\%$) as compared to IS $(\sim 90\%)$. Hence, no significant difference was recorded for the IS removal for both the commercial and PES-SS membranes.

Adding hydrophilic polymers has been a common surface modification technique for hydrophobic membranes to minimize problems in fouling that will lead to cascade of reactions such as platelet activation and complement system activation. However, hydrophilic polymers tend to swell in water which is eluded in dialysis process as it affects the removal efficiency of membranes.¹¹¹ Hence, exploration of blending synthetic polymer membranes with nanomaterials that can serve as inorganic fillers to avoid swelling is a growing trend in membrane technology.¹⁰¹

Carbon nanotubes (CNT) have been used as nanofillers for their nanoscale dimensions, which can offer high membrane specific surface area for interactions with contaminants or resources. In addition, both hydrophobic and hydrophilic blood components can interact with this material via π - π stacking and hydrogen bonding with oxygen-rich species (-COOH and -OH) in its chemical structure.¹¹¹ In the first study that fabricated multiwalled carbon nanotube (MWCNT)/PES membranes, poly(vinyl pyrrolidone) (PVP) was the other additive that was incorporated to avoid MWCNT aggregation while reducing the elution of PVP during filtration (Table 2, entry 11).111 Urea, creatinine and lysozyme were filtered at a rate of 125 mL min⁻¹ at the simulated blood solution side and 50 mL min⁻¹ at the pure water solution side which gave higher removal efficiencies of 56.3% for urea, 55.1% for creatinine and 27.9% for lysozyme than the unmodified membranes. These values are relatively low compared to the performance of other mixed matrix membranes (MMMs) that incorporated inorganic nanofillers (Table 2, entries 3 and 6) and also filtered urea⁹⁹ (~97%) and lysozyme¹⁰⁰ (~36%). Possible reasons could be the tendency of PVP to leach after prolonged hours of filtration and the inadequate amount of added MWCNT (0.05-0.2 g) to sustain PVP in the matrix. Hence, another MWCNT/ PES MMM membrane was proposed which used MWCNT-grafted poly(citric acid) (PCA) as another additive instead of PVP.¹⁰¹ Hydrophilic poly(citric acid) was grafted with MWCNTs since MWCNTs are more well-dispersed when grafted with polymers and other large organic molecules than grafting with acid alone.¹²⁰ Addition of solid oxidized (O)-MWCNTs in the PES dope solution increased the solution viscosity from 5121 to 7797 mPa s. However, when the PCA-g-MWCNTs were added, a reduction of viscosity from 7797 mPa s to 6564 mPa s was recorded. This result is an implication of the inverse relationship between the viscosity and the average size or molecular weight distribution of MWCNT. An increase in the molecular weight of the PCA-g-MWCNTs led to greater shear rate thus lesser solution viscosity. As a result, larger voids were formed leading to a lower BSA absorption of 65.3% than the unmodified membrane.

3.2.3. Poly(lactic acid) membranes. Despite the biocompatibility of the current synthetic polymer haemodialyzers such as PSf and PES, waste disposal issues arise given that these membranes are for single-use only.^{121,122} Hence, aside from biocompatibility, there has also been an increasing research on materials that are both biocompatible and biodegradable.¹²³ Poly(lactic acid) (PLA), a biocompatible polymer, has been used as the base membrane in some haemodialyzers because of its biodegradability however, its hydrophobicity makes it prone to fouling like PSf and PES membranes.¹²⁴ Hence, PLA grafted with an amphiphilic block co-polymer, poly(2-hydroxyethyl methacrylate) (PHEMA) was being developed for better durability and antifouling capacity (Table 2, entry 16).⁶⁸ Grafting of PHEMA with PLA was done via reversible addition-fragmentation (RAFT) polymerization from aminolyzed PLA. Briefly, aminolysis reaction of PLA with ethylenediamine (EDA) formed PLA-EDA which was used to synthesize PLA-CDP from 4-cyano-4-(dodecylsulfanylthiocarbonyl)sulfanylpentanoic acid (CDP) via esterification/amination between the hydroxyl (-OH)/amino

(-NH₂) groups of PLA-EDA and the carboxyl (-COOH) groups of CDP. PLA-CDP was used as a macromolecular chain transfer agent during RAFT polymerization. HEMA and the initiator, azobisisobutyronitrile (AIBN) was added to PLA-CDP under 70 °C with constant stirring at an inert atmosphere forming the block copolymer PLA-PHEMA. Ultimately, PLA-PHEMA was added to PLA to form a more hydrophilic PLA/PLA-PHEMA membranes. Water contact angle measurements were obtained, and it was observed that the contact angles decreased from 75.8° in pristine membranes to around 71.4°-60.5° in PLA/PLA-PHEMA membranes confirming increase in hydrophilicity. When clearance for urea, creatinine, lysozyme and BSA were compared (Fig. 2d), it was observed that there is no significant difference in the clearances of small solutes such as urea $(0.78 \text{ mL min}^{-1})$ and creatinine $(0.74 \text{ mL min}^{-1})$ for both the pristine and modified membranes. However, when larger solutes such as lysozyme and BSA were compared, it was observed that lysozyme clearance increased from ~ 0.15 mL min⁻¹ in pristine membranes to ~ 0.7 mL min⁻¹ in PLA/PLA-PHEMA membranes and BSA clearance was also increased from $\sim 0.05 \text{ mL min}^{-1}$ to ~ 0.35 mL min⁻¹. Hence, PLA/PLA-PHEMA membranes can be developed further for removal of middle molecular weight toxins in blood plasma.

3.2.4. Poly(ether imide) membranes. Most of the studies mentioned focused on the biofouling problem of most haemodialyzers and plasma filters but only few studies actually measured platelet and complement system activation on these membranes and the impact of membrane surface modification on blood coagulation proteins. Studies on how surface modification affect these remaining gaps were summarized in Table 3. Activated partial thromboplastin time (APTT), prothrombin time (PT) and plasma re-calcification time (PRT) were measured via coagulation analyzers and assays to evaluate platelet and complement system activation. APTT, PT and PRT are general testing procedures to evaluate coagulation abnormalities in the blood coagulation pathways. APTT is for the measurement of coagulation abnormalities in the intrinsic pathway composed of clotting factors such as factor IX, X and XI and is activated by collagen whereas PT is for the measurement of coagulation abnormalities in the extrinsic pathway - pathway activated by trauma in the vascular system, platelets, exposed endothelium or chemical which is composed of clotting factors such as factor VII and III.¹²⁵ Generally, when these parameters increase, it means that the interaction between the blood and membrane surface took longer for platelets to be activated subsequently triggering a cascade of reaction in the intrinsic pathway. Previous studies showed that the use of inorganic nanofillers such as MWCNTs and metal oxides improved the antifouling capacity of membranes^{99–101} but a study confirmed the haemocompatibility of a biocompatible polymer, poly(ether imide) (PEI) by measuring APTT, PT and PRT of pristine PEI and graphene oxide incorporated PVP-PEI membranes. Graphene oxide is a two-dimensional material that is an oxidized form of graphene. Graphene consists of a single layer of carbon arranged in sp² bonded aromatic structure.¹²⁶ Graphene oxide (GO) is now used as an inorganic nanofiller for its ultrathin

structure and high mechanical strength contributing to high throughput in membranes.¹²⁶ Since 2D materials have limited biocompatibility, haemocompatibility testing was done in this study to ensure minimized platelet activation (Table 3, entry 2). APTT, PT and PRT increased from 32 s, 15 s and 325 s in unmodified membranes to 75 s, 18 s and 675 s in modified membranes, respectively. The results show that by adding GO to the PEI/PVP membrane, there is a decreased interaction between the hydrophobic plasma proteins and blood since GO facilitates better incorporation of PVP with PEI and GO itself has hydrophilic moieties that will repel these proteins.¹¹¹

3.3. Conclusions for membrane-based apheresis

Membrane apheresis is one of the most promising blood apheresis technology for its scalability and versatility. From an operational point of view, the focus of membrane apheresis has been directed towards minimizing surface fouling by applying such material modification methods to improve performance and conserve hospital resources by reducing procedure duration.²⁵ This strategy is implemented by ensuring that an increased amount of blood toxins is removed to prevent compromising of the quality and purity of the extracted cells and of the filtered blood that will be returned to the patient at the end of the apheresis procedure. However, only few studies elaborated on the causes for these materials' enhanced performance, in terms of chemical or surface/interfacial energy changes.^{74,84} A drive towards improved selectivity in blood apheresis is also required due to the large range and complexity of blood components exhibiting wide size distributions and biochemistries. Efficient speciation of certain components, which are the cause of diseases or of industrial value, may be currently hampered due to the presence of other similarly sized materials. One such example is related to the extraction of IgG and the competitive transfer of albumin during membrane apheresis.^{61,127} In addition, testing the haemocompatibility of the added material to ensure applicability on extracorporeal blood purification is not yet performed systematically, which should become a good practice with materials scientists to develop relevant materials solutions.128,129

4. Adsorption-based apheresis

Sorbent apheresis technologies are developed to typically remove unwanted blood components using separation mechanisms beyond diffusion and convection.⁴ Specifically, selective sorbent materials for haemoperfusion have been developed since the 1970's for treatment of drug poisoning, to treat immunological diseases and remove uremic toxins.^{4,130} Some common uremic toxins that must be separated from blood are urea, creatinine and bilirubin. Urea and creatinine are toxic by-products of muscle and protein metabolism and high levels of these toxins implies impaired kidney function.¹³¹ Meanwhile, bilirubin is a by-product of red blood cell metabolism and high bilirubin levels indicates impaired liver function.¹³² Removal of bilirubin is necessary as this toxic metabolite can cause jaundice or condition where skin appears yellow.¹³² Separation of these toxins using these sorbent technologies is promising since, as opposed to centrifugation or membrane separation, only solutes of interest are retained through physical or chemical adsorption processes (schematic diagram on Fig. 3a).¹³³

Leaching or release of sorbents over time however, remains a major challenge most especially if the material is not biocompatible, causing adverse effects to the patient such as chills, fever, cutaneous rush, thrombocytopenia and leukopenia.⁴ Strategies to minimize such adverse reactions or immunological responses from the body such as containing the adsorbents within specifically designed cartridges or modules are critical to allow for proper and safe operation and direct contact with the blood.¹³⁴ Two solutions have emerged involving (i) separation of the plasma from the blood cells prior to




Fig. 3 Adsorption-based apheresis. (a) Affinity-based separation. A ligand or sorbent attached to the column surface attracts the blood component of interest by affinity due to charge or shape complementarity. (b) An example of sorbent for direct haemoperfusion. Poly(aramid)–GO/PSS gel beads were crosslinked *via* π – π interactions.¹³⁶ (c) An example of sorbent for plasma perfusion. Biocompatibility of sorbents is increased by coating with a hydrophilic polymer. Micrometre-size magnetic carbon fibres (MSMCF) are functionalized with a more stable poly(dopamine)/poly-(ethylene imine) (PDA/PEI) coating by crosslinking the magnetically separated MSMCF/PDA/PEI mixture using glutaraldehyde to form PDA/PEI-modified MSMCF.¹³⁷ (d) Metal–organic frameworks (MOFs) as adsorbent. Mechanism of capture for two cage-based MOFs were shown. High specificity toward bilirubin is demonstrated by dissociation of blood protein from the bilirubin/protein complex after capture.¹³⁸

Application

haemoperfusion

Direct

Plasma

perfusion

Direct and

perfusion

plasma

Plasma

Direct

Plasma perfusion

Direct

Plasma

Direct haemoperfusion

Plasma

perfusion

perfusion

perfusion

haemoperfusion

haemoperfusion

(leukoreduction)

Review

Table 4 Sorbents used for haemoperfusion and the corresponding modifications for enhanced adsorption capacity

BET surface

area

1250

146

900

ND

795

ND

210

ND

183

2060-4000

 $(m^2 g^{-1})$

Adsorbed

component

Creatinine

Indoxyl sulfate

Hippuric acid

blood

(IS)

(HA) Interleukin-6

(IL-6) Interleukin-8

(IL-8)

Bilirubin

Free and

chelated

gadolinium

gadopentetate

dimeglumine and

gadodiamide)

Bilirubin

Creatinine

Bilirubin

Bilirubin

Creatinine

Low density

lipoprotein (LDL) Bilirubin

α-Amanitin

β-Amanitin

CCR-9 expres-

sing cells

Ampicillin

sodium

 Cu^{2+}

Adsorption

gram or %)

~14 mg

 \sim 3.7 mg

 $\sim 13 \text{ mg}$

 $\sim 33 \text{ ng}$

 $\sim 80 \text{ ng}$

335 mg

30 min

99% in 1 min

(free); 95% in

(gadodiamide)

 $\sim 1003 \text{ mg}$

97%

79%

50%

560 mg

15 mg

18 mg

228 mg

98%

13.5 mg

~91-96%

 $\sim 90 - 92\%$

capacity (per

-				
Entry	Sorbent	Sorbent modification?	Type of sorbent modification	Pore size (nm)
1	Carbon-based sorbent materials ¹⁴⁰	No	ND^{a}	0.8–1 and 5
2	Magnetic carbon fibre ¹³⁷	Yes	Coated with dopamine- poly(ethylene)imine (PEI)	35 and 5200
3	Nanostructured silica materials ¹⁵³	Yes	Functionalization with 1-hydroxy-2- pyridinone (1,2- HOPO-SAMMS)	~6
4	Cage-based metal organic frameworks (MOFs) ¹³³	No	ND	1.84–5.5 (cage size)
5	Kevlar-based composite gel beads ¹⁴²	Yes	Crosslinking of sodium <i>p</i> - styrenesulfonate (SS) onto Kevlar- graphene oxide (GO) interface	50 000 (gel shell)
6	Non-ionic microporous poly(styrene adsorbent) ¹⁵⁶	No	ND	4.8
7	Heparin- mimetic gel beads ¹⁴⁵	Yes	Crosslinking of carrageenan and poly(acrylic acid) networks	32 000- 22 000
8	Molecularly- imprinted biomimetic adsorbent ¹⁵⁷	No	ND	3.6
9	CCL-25 columns ¹⁴⁶	No	ND	ND
10	Solid phase extraction	No	ND	2.75

circulation through the sorbent bed or (ii) the coating of the not offer control over the fluid balance and the ability to sorbent materials with a secondary bio- or haemocompatible remove other contaminants simultaneously, such as urea.¹⁴⁰ material.¹³⁵ The applicability and throughput of these strate-

4.1.1. Carbon-based sorbent materials. Semi-continuous carbon-based sorbent materials with tailored dual pore size distributions were designed to ensure that both small solutes such as urea and larger protein-bound uremic toxins, β_2 -microglobulin and cytokines could be simultaneously adsorbed (Table 4, entry 1).¹⁴⁰ CMK-3 type carbon adsorbents were synthesized to exhibit both micropores (<2 nm) and mesopores (2-50 nm). The sorbent produced via a pyrolysis process consisted of a set of parallel rods hexagonally packed and

7224 | Mater. Adv., 2021, 2, 7210-7236

gies will be discussed in this section.

4.1. Sorbents for direct haemoperfusion

In direct perfusion columns, adsorbent cartridges are used to

be in direct contact with blood within the column housing.¹³⁹

In this apheresis mode, the micron-sized sorbent particles

provide fast and efficient removal capacity of all the toxins they are designed to capture. However, direct haemoperfusion does

adsorbent158 ^a Abbreviation: ND, no data.

interconnected with thin carbon strands. The pore size distribution within the rods ranged between 0.8 and 1 nm, which was effective in capturing small water-soluble molecules and protein-bound toxins (PBTs). The space between the rods generated a well-defined and easily tuneable mesoporous matrix with narrow pores, on the order of 5 nm, which enabled the removal of low molecular weight molecules (<500 Da, <10 nm)^{94,95} and cytokines without hindering diffusion across the micropores. A wide range of solutes was demonstrated, ranging from creatinine, β_2 -microglobulin, PBTs like hippuric acid (48% bound to HSA) and indoxyl sulphate (98% bound to HSA), as well as the removal of two cytokines, IL-6 and IL-8. The performance of the CMK-3 adsorbents was compared with two commercially available carbon-based sorbents (Norit A Supra, 3 nm and Takeda 5 A, 0.6 nm). For creatinine, the CMK-3 and Norit A Supra exhibited superior adsorption capacity than the Takeda 5 A, which was attributed to their higher specific surface areas (SSA) between 1250 and 1700 $m^2 g^{-1}$ for the CMK-3 and Norit A, respectively, compared to only 560 m² g⁻¹ for the Takeda resins. The SSA normalized adsorption capacities of CMK-3 was higher compared to the Norit A Supra, at 14 mg and 11 mg/1000 m² for CMK-3 and Norit A, respectively. The capture of PBUTs was similar and the CMK-3 offered a slightly higher specific SSA adsorption capacity for IS $(\sim 2.9 \text{ mg}/1000 \text{ m}^2 \text{ vs.} \sim 2.2 \text{ mg}/1000 \text{ m}^2)$ and HA (10.1 mg/ 1000 m² vs. 9.8 mg/1000 m²) than Norit A. The scalability of the process with CMK-3 was discussed and it was shown that in this scenario, only 128 and 22 g of the adsorbent were required to remove either creatinine or PBUTs. As a benchmark, a kidney patient generates daily creatinine production on the order of \sim 1800 mg, while the mean daily excretion of IS and HA is on the order of 69 mg and 270 mg, respectively.¹⁴¹ The capture of medium molecular weight molecules and cytokine clearance with CMK-3 was demonstrated with up to 42% of IL-6 and 68% of β_2 -microglobulin removal in the same experimental conditions, whereas Norit A (0 ng g^{-1}) and Takeda (0 ng g^{-1}) performed extremely poor for cytokine removal. The Takeda resin however, was able to remove 22% of the β_2 -microglobulin.

4.1.2. Poly(aramid)-based composite gel beads. Direct haemoperfusion was performed with poly(aramid)-based composite gel beads (Table 4, entry 5 and Fig. 3b).¹⁴² Poly(aramid) nanofibres were utilized as a scaffold and combined to graphene oxide (GO).¹³⁶ First, poly(aramid) nanofibre - GO beads were produced by liquid-liquid phase separation. Then, π - π interaction of sodium-p-styrene sulfonate (SS) onto the poly(aramid)-GO interface was initiated by ammonium persulphate (APS) to form composite poly(aramid)-GO-poly(styrene sulfonate) (PSS) beads with an interfacial cross-linked structure. The composite K-GO/PSS beads exhibiting a dual-network structure and a heparinmimicking gel structure were obtained and haemoperfusion experiments showed an increase in capture capacity by 97% (~350 $\mu g \ m L^{-1}$ beads) for creatinine and 79% (~5610 $\mu g \ m L^{-1}$ beads) for bilirubin compared to poly(aramid) alone ($\sim\!110\,\mu\mathrm{g}\,\mathrm{mL}^{-1}$ beads and $\sim 2810 \ \mu g \ m L^{-1}$ beads for removal of creatinine and bilirubin, respectively). The haemocompatibility study was however performed with platelet-poor plasma as the control, reducing the

relevance of the work. The indicators of platelet activation for APTT, TT and PRT increased from ~44 s, 21 s and 255 s for the control materials to ~66.4 s, 38.8 s and 14 400 s, for the modified samples, and this trend indicated that platelet activation was inhibited. PTT remained at similar concentration for both the control and the modified beads at ~12 s, which indicated that extrinsic coagulation pathways were not activated. Observing the serum concentrations of the anaphylatoxins C3a and C5a as indicators for complement activation, the serum C3a concentration only increased from 1750 ng mL⁻¹ to 1900 ng mL⁻¹ while the serum C5a concentration only decreased from 38 ng mL⁻¹ to 32 ng mL⁻¹ which is not clinically relevant. Since C5a is a more potent chemoattractant than C3a, K-GO/PSS did not induce inflammatory response from these mediators upon contact of blood to the beads which confirms its haemocompatibility.

4.1.3. Heparin-mimicking adsorbents. Natural-based adsorbents extracted from raw materials such as zeolites (aluminosilicate) and porous carbons (cellulose-derived organic polymers prepared by controlled thermal oxidation) exhibit some level of an inherent biocompatibility.^{143,144} However, the relatively poor mechanical strength and low surface functional group contents available for surface modification remain a challenge towards implementing such sorbents. Heparin-mimicking carrageenan and poly(acrylic acid) (PAA) cross-linked networks were synthesized via combination of phase inversion of carrageenan and post-crosslinking of AA. The beads with dual-network structures have improved mechanical properties and controlled swelling ratios (Table 4, entry 7).¹⁴⁵ The average pore size post modification decreased from 32 µm to 22 µm. Adsorption capacities improved from 150 mg g⁻¹ to 560 mg g⁻¹ for Cu²⁺, 6 mg g⁻¹ to 15 mg g^{-1} for creatinine, 1.5 mg g^{-1} to 18 mg g^{-1} for LDL and from 100 mg g^{-1} to 228 mg g^{-1} for bilirubin compared to the carrageenan reference. The improvement in the adsorption capacities can be associated with the presence of a large density of negative and oxygen-containing functional groups, which enabled strong interactions with the positively-charged probe molecules. Haemocompatibility tests and indicators of antithrombogenicity such as APTT, PT and TT all increased from 44.5 s to 413.9 s, 13.3 s to 51.6 s and 18.1 s to 60.1 s, respectively supporting that intrinsic, extrinsic and common coagulation pathways were activated at a very minimal rate. Serum plasma concentrations of anaphylatoxins C3a and C5a, were also observed and decreased from 3250 to \sim 2900 ng mL⁻¹ and 80 to 38 ng mL⁻¹, respectively. This trend demonstrated that no trigger of the complement system occurred, which should limit risks for allergic reactions and inflammatory responses.

4.1.4. Biotinylated columns. CCL-25 columns were also developed for direct haemoperfusion to remove over-expressed CCR9 cells in patients with inflammatory bowel disease (IBD).¹⁴⁶ Compared to commercially available Adacolumn[®] made up of cellulose acetate beads, this column offered more specific adsorption mechanisms for certain types of leukocyte and CCR9-expressing cells thanks to the interactions between chemokine and the corresponding cell surface receptors. Streptavidin-conjugated sepharose beads were selected as carrier matrices for their high affinity with biotinylated chemokine, CCL-25

Materials Advances

 $(K_{\rm d} 4 \times 10^{-14})$ and such biotinylated columns were found to be highly selective towards CCR9-expressing cells. In fact, 98% of the CCR9-expressing cells in healthy donors were reduced leading to depletion of at least 100×10^6 cells.

4.2. Sorbents for plasma perfusion

Plasma perfusion adsorbents consist of a base material coated with an active functional ligand layer for selective coordination of plasma components.¹³⁹ During plasma perfusion, the extracted plasma from a plasma separator is flushed through a column containing the adsorbents to prevent damage to the cellular components, known to reduce the adsorption efficiency of the process significantly.¹³⁹

4.2.1. Magnetic carbon fibres. The possibility of magnetic materials as blood-cleansing adsorbent for non-invasive treatments of various diseases, such as sepsis, was demonstrated by tagging particular etiological components, corresponding to disease-causing agents, prior to letting them interact with a magnetic material.¹⁴⁷ Carbon fibres are thread-like carbon materials with excellent mechanical performance and multiple functional properties including low-levels of magnetic properties.¹⁴⁸ Such materials may contain micro- and mesopores or be modified through specific activation-etching schemes to increase the pore density.¹⁴⁹ Micrometre-sized magnetic carbon fibre coated with poly(dopamine)/poly(ethylene imine) complexes (PDA/PEI-modified MSMCF) were developed for the adsorption of bilirubin (Fig. 3c).137 Since the surface of the carbon fibres is not natively active, incorporating other polymers may be challenging.¹⁵⁰ The introduction of a poly(dopamine) (PDA) coating via hydrophilic crosslinking with glutaraldehyde, led to instabilities caused by the inherently strong interactions of the catechol chemical structure with the dopamine monomer. As a result, the modified magnetic carbon fibres yielded relatively comparable total bilirubin clearance (14-66% within 2 h equilibrium adsorption) with HSA-immobilized magnetic beads (31% within 2 h)151 and lysine-attached aluminium oxide-silica membrane (35% within 4 h).¹⁵² An increased PRT from 282 s to 318 s and a decreased serum concentration of anaphylatoxins C3a and C5a from 45 ng mL^{-1} to 25 ng mL^{-1} and from 1.9 ng mL^{-1} to 1.0 ng mL^{-1} , respectively were recorded for MSMCF/PDA/PEI compared to MSMCF alone showing that this sorbent is haemocompatible.

4.2.2. Nanostructured materials as adsorbents. Nanostructured materials offer very high surface area and chemically selective functionality which allows for tailoring of the 3D architecture, pore size, and interfacial chemistry.¹⁵³ Self-assembled monolayers on mesoporous silica supports (SAMMS[™]) were used as sorbents for both free and chelated gadolinium (Gd) in the treatment of patients with chronic kidney disease and nephrogenic systemic fibrosis (NSF) – a condition wherein the skin of extremities tightens and swells accompanied by weakness of muscles limiting the ability to move.¹³⁸ These SAMMS[™] were functionalized with 1-hydroxy-2-pyridinone (HOPO) using 3-aminopropyltrimethoxysilane as coupling agent.¹⁵⁴ HOPO-complexing agents were selected with SAMMS[™] for their ability to sequester heavy metals in nuclear waste.¹⁵⁵ Upon application in

haemoperfusion, HOPO-functionalized SAMMSTM were able to adsorb 99% of free Gd within 1 min and 95% of chelated Gd within 30 min. An advantage of this approach is that the continued use of Gd-contrast magnetic resonance imaging (MRI) can be performed to avoid NSF in renal patients. Cagebased metal organic frameworks (MOFs) also showed a recordhigh selective adsorption of bilirubin (~1000 mg g⁻¹) which is over 69 times higher than clinically approved activated charcoal materials (Fig. 3d).¹³³ This adsorption capacity was attributed to the multiple π - π interactions with parallel-displaced configurations formed between the aromatic rings of bilirubin and ligand of the MOF which is 4,4,4-*s*-triazine-2,4,6-triyl-tribenzoic acid (H₃TATB). Therefore, such nanostructured materials represent clear avenues to yield enhanced removal rates and selectivity towards specific blood components.

4.2.3. Non-ionic microporous polymer adsorbents. A nonionic microporous poly(styrene) adsorbent, SZ-9, was also developed to avoid the activation and coagulation cascade caused by the strong basic functional groups within commercial adsorbent columns (BL-300) made from a porous anion exchange resin coated with hydrophilic 2-hydroxyethylmethacrylate copolymer.¹⁵⁶ Gas adsorption analysis of the SZ-9 and BL-300 adsorbents to determine the pore size distribution showed that the SZ-9 adsorbents were made up of highly porous, uniformly shaped spherical beads with a Lorentzian pore size distribution between 10 and 50 nm, and a mean value at \sim 20 nm. However, the BL-300 adsorbents are composed of irregularly shaped but narrower pores, ranging from 1 to 10 nm, for a mean value of 3 nm. The specific surface area of the SZ-9 was found to be higher (794.9 m² g⁻¹) than BL-300 (592.4 m² g⁻¹) with the average pore diameter (4.8 nm) found to be larger than that of BL-300 (3 nm). The dynamic adsorption data acquired for the total bilirubin, direct bilirubin, indirect bilirubin and total bile acid in the blood plasma on the adsorbents, showed that the SZ-9 performed better than the BL-300 and exhibited a slightly higher adsorption efficiency, ranging from 47% in BL-300 to 50% in SZ-9, for bilirubin. SZ-9 also exhibited negligible percentage of haemolysis (-0.4%) compared with BL-300 which was reported at $\sim 11\%$. Hence, these resins appear safe for application in the treatment of fulminant hepatitis and postoperative hepatitis using haemoperfusion.139

4.2.4. Molecularly imprinted adsorbents. Molecularly imprinting is also another material processing technology used to synthesize biomimetic adsorbents. α - and β -amanitin, two major types of mushroom poisons, were removed separately from blood using molecular imprinted materials.¹⁵⁷ The specific surface areas obtained using Brunauer–Emmett–Teller (BET) analysis for the molecularly imprinted vinylated silica microspheres were 0.021 m² g⁻¹ for the MIP compared to 0.017 m² g⁻¹ for the non-imprinted polymer, which were similar. However, high selectivity factors were calculated for the α - (6.53) and β - (6.21) amanitin which could be attributed to the difference in Trp-Cys cross-bridge located at the convex domain of these bicyclic octapeptide, which is the natural pattern of the amanitin molecule. Adsorption capacities of 92–95% for α -amanitin and 90–92% for β -amanitin were obtained compared

to 60–70% and 56–57% only for their corresponding nonimprinted polymer, respectively. Molecularly imprinted amino-functionalized silica particles were also used as solid phase extraction adsorbents to remove ampicillin sodium from blood samples (Table 4, entry 10).¹⁵⁸ Compared with the amanitin-specific vinylated silica particles, specific surface area of ampicillin sodium-specific silica particles obtained was higher at 183 m² g⁻¹ than the non-imprinted reference material (173 m² g⁻¹). The adsorption capacity of MIP is ~71% more than the NIP. Hence, molecularly imprinted materials are good adsorbents for separating stereo-selective or regio-selective molecules. Developments of such materials and integration into meso-porous scaffolds offer great promises towards flow-through adsorbents design.

4.3. Conclusions for adsorbent-based apheresis

Adsorbent-based apheresis is a technique that use affinitybased separation enabling specific molecule to capture through electrostatic interactions, hydrogen bonding or shape complementarity. Although adsorption is very efficient and promising overall selectivity, the process may still be improved, and novel surface chemistries must be developed to enable more selective capture mechanisms. The design of specific micro or nano pore distributions may also support performance, but pre-treatment is nevertheless required prior to operation to facilitate the adsorption process. Carbon-based sorbent materials are largely non-selective but represent an excellent scaffold material and their microstructures and pores may be tuned to allow for separation based on size.

The haemocompatibility and toxicity of the ligand materials used to build chemical adsorbents remain a challenge by hindering direct blood contact and adding costly cartridge designs. The grafting of antibodies was discontinued for instance due to strong side effects triggering platelet activation.¹⁵⁹ Hence, patient safety and disease indications should still be carefully monitored prior to selecting a base material for the sorbent.

5. Microfluidic-based apheresis

Microfluidic-based separation technologies emerged during the late 1970's and gained interest for their ability to separate very efficiently minute blood volumes of approximately up to one nanolitres with flow rates of up to 1 μ L min^{-1,5,28,160} Microfluidics is mainly applied during collection of blood components for novel therapies as part of clinical trials and for isolation of blood components for disease prognosis.¹⁶¹ The main speciation mechanisms rely on size and deformability of blood cells, and can be controlled using the fluidic properties, flow rate and channel geometry (schematic diagram in Fig. 4a).⁵

Separation by microfluidics technologies can be classified as active, passive or combined as in the case of label-free cell sorting mechanisms.²⁸ In active approaches, external force fields are applied to effect particle motion during blood fractionation.¹⁶² Active separation techniques can be based on magnetophoresis, whereby particles move in a magnetic field, acoustophoresis, if particles migrate with soundwaves, and dielectrophoresis, upon non-uniform electric field application.²⁸ Passive techniques do not require external forces to drive the separation and rely on the interaction of phenomena including diffusion, hydrodynamic forces such as inertial and Dean's forces, and the intrinsic physical properties of the cells including size and deformability.^{28,161,163}

The fabrication material employed by most current microfluidic devices developed for diagnostic apheresis is poly-(dimethylsiloxane) or PDMS – a transparent and inert polymer that is inexpensive.¹⁶⁴ It is commonly used for purposes of blood component separation because aside from it is nontoxic, it entails very simple device fabrication.¹⁶⁴ Other materials that can be used are glass and various thermoplastics, which can




Fig. 4 Microfluidic-based apheresis. (a) An example of microfluidic separation.¹⁶⁵ As blood sample is introduced, the plasma (liquid component) exerts rotation-induced lift force on the sphere-like blood components such as leukocytes, erythrocytes and platelets which causes size-based lateral migration. (b) Materials used for device fabrication of apheresis chips.^{145,166} Poly(dimethylsiloxane) or PDMS is the most commonly used but glass is also employed for blood component separation. (c) Comparison of microfluidic apheresis device with already established apheresis techniques (centrifugation and membrane filtration). Total plasma protein recovery (left) is significantly higher than the protein recovery obtained after membrane filtration considering the amount of agglutination antibody protein incorporated with the device Effects of surface treatments such as treating with poly(ethylene glycol)methyl ether methacrylate (PEGMA) solution, hydroxyethylmethacrylate (HEMA) solution, bovine serum albumin (BSA) solution and oxygen plasma (right) show that BSA treatment gave the highest % recovery rate considering also the amount of agglutination antibody incorporated with the device.

Materials Advances

also be biocompatible but in the prototyping stages fabrication process fabrication can be more complex and have higher infrastructure demands than making PDMS devices by soft lithography.¹⁶⁴ Hence, this section will focus on device design principles aside from the fabrication materials used and the surface modification applied towards these materials to increase separation efficiency, throughput and recovery (Table 5).

5.1. Microfluidic devices for leukapheresis

Current leukoreduction retains leukocytes via a membrane filtration process while allowing other blood components to pass with the flow through the pores prior to returning to the body. Membrane fouling, platelet activation and complement system activation are key challenges of membrane apheresis. In order to address this limitation, a high-throughput passive microfluidic device to remove leukocytes from platelet-rich plasma (PRP) in a continuous flow regime using controlled incremental filtration (CIF) was developed (Table 5, entry 1).¹⁶⁷ Here, leukocytes were separated from platelets within the PRP by progressively syphoning clarified PRP away from the concentrated leukocyte flow stream. Poly(dimethylsiloxane) (PDMS) was the material used to fabricate the device replicas for separation runs but these replicas were treated with 1% (w/v) aqueous solution of methyl-end capped trimethoxy poly(ethylene glycol) silane (mPEG-silane) to reduce protein adsorption and fouling.¹⁶⁸ Uncoated PDMS can lead to higher fibrinogen adsorption causing more immediate platelet activation.169 Using this device, 99.9% of leukocytes were removed based on the filtrate PRP while recovering >80% of the original platelets at volumetric throughputs of $\sim 1 \text{ mL min}^{-1}$. These results suggest that CIF approaches will enable users in many fields to exploit microfluidic phenomena, even at throughputs nearing the flow rates used for continuous flow centrifugation ($\sim 50 \text{ mL min}^{-1}$).

Integrated micro-fabricated filters were used for the separation of leukocytes (Table 5, entries 2 and 3) based on deformability.^{170,171} Initially, microfilters with gap sizes gradually decreasing from 15 to 3 µm were used.¹⁷⁰ The distribution of captured cells was analysed for different flow rates, cell sizes and cell deformability. Changes in fluidic behaviour with variation in flow rates allowed for the collection of leukocytes of different sizes at different flow rates. At high sample flow rate $(6 \ \mu L \ min^{-1})$, small leukocytes particularly lymphocytes with a size of 7 µm permeated across the smallest microfilter gap size of 3 μ m, whereas at lower flow rates (1.5 μ L min⁻¹), lymphocytes were captured in a 6 µm microfilter gap size. Although this system offers a low sample throughput compared to the CIF device,¹⁶⁷ it does offer a high separation efficiency for WBCs (100%) with regard to other blood components such as cancer cells and RBCs.

Another filter-integrated device based on diffusion in a continuous flow was developed,¹⁷¹ where the geometry of the diffuser was optimized to ensure that the fluid distributes equally across the individual sieve elements. When a flared geometry was used, a separation efficiency of >97% was achieved for leukocytes at a higher sample throughput (5 μ L min⁻¹) than previously reported for microfluidic devices (1.5 μ L min⁻¹).

Hence, the optimised geometry supported greater throughput. The device is versatile since it can also be used for plasma fractionation by reducing the height of filter elements from 2.5 μ m to <0.5 μ m. Leukocyte and erythrocyte separation however, depends mainly on pressure gradient across filter elements which is a function of operating flow rate and in this case, higher flow rates will permit stronger interaction between the leukocytes and erythrocytes with the filter elements than lower flow rates.

5.2. Microfluidic devices for erythrocytapheresis

Erythrocytes may also be separated from whole blood for blood donation or red cell exchange.⁴¹ Two types of passive microfluidic device that are based on crossflow filtration were fabricated to separate RBCs from whole blood (Table 5, entries 4 and 5).¹⁷² Microstructures including as micro-pillar arrays and micro-weirs were used in a filtration device. PDMS was still the main fabrication material of choice but in the first chip (Table 5, entry 4),¹⁷³ glass is compounded with PDMS over a silicon substrate. Considering the microstructures incorporated with the device, the rationale for the material of choice could be the fact that glass compensates for the elasticity of PDMS which may affect accuracy of the fabricated channel dimensions.¹⁷⁴ In terms of the mode of membrane filtration, cross flow filtration was used as opposed to dead end filtration to ensure large particles remain suspended while the small particles permeate through the filter; in dead-end filtration large particles may clog or jam the pores.^{175,176} Consequently, by employing the design principle and fabrication material, separation efficiencies were greater than 95% and 27% for RBC and WBC, respectively.

Besides incorporating filters within the microfluidic device, a passive microfluidic chip driven by the inertial migration effect was also developed to separate and enrich leukocytes from whole blood.¹⁷⁷ The chip design incorporated 10 switchback curve channels bridged by straight channels for inducing inertial migration effects to concentrate the blood cells while the curved channels were integrated for inducing Dean flow – a secondary cross-sectional force field characterized by the two counter-rotating vortices perpendicular to the direction of the flow for further separation of cells based on their sizes.¹⁷⁸ This configuration led to the very high erythrocyte separation efficiency with almost no erythrocyte loss (~100% capture efficiency) while still recovering ~93.2% of the leukocytes from whole blood.

5.3. Microfluidic devices for circulating tumour cell (CTC) isolation

Circulating tumour cells (CTCs) are cancer cells that migrate away from primary site and are distributed throughout the body using the bloodstream.¹⁴⁵ CTCs are considered attractive biomarkers for cancer diagnosis/prognosis as sampling blood may be less invasive than taking tumour biopsies.¹⁷ However, their very low concentration (1–100 CTCs per mL of blood) makes their detection challenging.¹⁷⁹ So far, CTCs can be separated based on their physical properties such as size and deformability since CTCs have comparable sizes as other blood cell

Recovery (%)	> 80 (platelets)	100	(leukocytes) ~50 (ervthrocytes)	~27	93.2 (leukocytes)	83–93	99.9 (leukocytes)	>86 (CTC)	ND^{a}	> 82	<20	
Separation efficiency (%)	6.66	100	> 97	85.3 (pillar-type); 93.3 (weir-type)	~ 100	> 99.3	> 93	86 99.97 > 99.99	8-26	11	6.66	
Blood component separated	Leukocytes	Leukocytes	Leukocytes	Erythrocytes	Erythrocytes	Circulating tumor cells	Circulating tumor cells	Circulating tumor cells Leukocytes Erythrocytes Platelets	Plasma	Plasma	Plasma	
Sample volume/ throughput (µL min ⁻¹)	1000	1.5	ß	10	Chip 1:15 000 Chip 2:6000	300	200	2800	ND ^a	17	ND^{a}	
Injected sample	~ 2–3 mL freshly donated platelet- rich plasma	10 μL human blood	samples 1 mL whole blood	100-Fold dilution of blood samples	Human whole blood with 4.3 \times 10 ⁸ cells per mL	Spiked cancer cells	Spiked samples containing target cells	64 mL whole blood spiked with cancer cells	0.5 μL fresh human blood and 7.5 μL buffer	90 μL whole blood	$< 10 \ \mu L$ whole blood	
Separation mechanism	Controlled incremental filtration	Microfiltration	Continuous flow diffision	Crossflow filtration	Hydrodynamic and inertial forces	Size-dependent inertial migration	Hydrodynamic separation	Magnetic sorting	Electro-osmotic flow	Capillary flow driven by blood agglutination	Gravity and capillary flow-driven	
Active/ passive	Passive ¹⁶⁷	Passive ¹⁷⁰	Passive ¹⁷¹	Passive ¹⁷²	Passive ¹⁷⁷	Passive ¹⁶⁵	Passive ¹⁴⁵	Active ¹⁷	Active ¹⁸⁵	Passive ¹⁸⁹	Passive ¹⁶⁶	
Surface modification for efficient separation	Treated with 1% (w/v) aqueous solution of mPEG-silane	PDMS bonded to glass slide	after oxygen plasma treatment PDMS bonded to glass slide after oxvøen nlasma treatment	Glass compounded over a silicon substrate	PDMS bonded to glass slide after oxygen plasma treatment	PDMS bonded to glass slide after oxygen plasma treatment	D GN	PDMS bonded to glass slide after oxygen plasma treatment	PDMS bonded to glass slide after oxygen plasma treatment	Treatment with PEGMA, HEMA, BSA and oxygen plasma	Öxygen plasma treatment	
Fabrication material	Poly(dimethylsiloxane) (PDMS) mixture	Poly(dimethylsiloxane)	Poly(dimethylsiloxane)	Poly(dimethylsiloxane)	Poly(dimethylsiloxane)	Poly(dimethylsiloxane)	Glass	Poly(dimethylsiloxane) for magnetic sorter; medical grade cyclic olefin copolymer (for inertial separation array device)	Poly(dimethylsiloxane)	Off-stoichiometry thiolenes	Poly(dimethylsiloxane)	^{<i>a</i>} Abbreviation: ND, no data.
Entry no.		5	3	4	ى ا	9	~	∞	6	10	11	^a Abbre

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

Open Access Article. Published on 18 October 2021. Downloaded on 5/26/2025 6:03:26 AM.

(cc) BY-NC

© 2021 The Author(s). Published by the Royal Society of Chemistry

Table 5 Microfluidic devices for blood apheresis and mechanisms adapted for high separation efficiency and throughput

Materials Advances

components.¹⁸⁰ Filtration-based separation can address challenges regarding low expression of protein marker for CTCs (epithelial cell adhesion molecule or EpCAM) however, filtration will not be able to extract CTCs from other blood components with similar sizes. Hence, filter-free microfluidics provides an attractive platform for CTC isolation.¹⁸¹ Affinity-based separation can also be done for these blood components.¹⁸¹ The most clinically-validated current commercial technology available to separate EpCAM from whole blood which implements affinity-based separation is the FDA-approved CellSearch[®] System which contains ferrofluids with EpCAM antibodies. The specificity towards EpCAM clearance is high and ranging between 89 and 93% using this technique.^{182,183} However, the sensitivity remains low with a very broad result distribution, and on the order of 27 to 70%.^{182,183} Hence, other approaches are still being explored to separate EpCAM from blood.

A passive, multi-flow microfluidic channel was used to isolate CTCs in lung cancer patients (Table 5, entry 6).¹⁶⁵ This device was designed for separation based on size-dependent inertial migration. Rotation-induced lift force (F_{O}) was the predominant force behind the size-based lateral migration and subsequent CTC isolation. The blood sample and phosphate buffer were introduced using a sample inlet and buffer inlet channel, merging to forming a sandwiched flow configuration in the main channel. The CTCs were collected from the inner outlet whereas other cells outside the size cut-off were collected from the outer outlet. To assess device performance, cancer cells spiked with poly(styrene) particles were used. Consequently, >99% of the spiked samples were isolated with purity of >87% and recovery of >93%. However, red blood cell contamination is an issue during sample preparation since the device isolated CTCs directly from whole blood thus additional cell lysis step for RBCs was required before separation. Samples were also not directly analysed by the instrument, which required immune-phenotyping post speciation.

Meanwhile, a passive, glass wedge-shaped microchip was also used to isolate CTCs from gastric cancer patients (Table 5, entry 7 and Fig. 4b).¹⁴⁵ The wedge-shaped chamber provided functionality to the device by gradually decreasing the chamber height which allowed a wide outlet causing blood cells to not clog the channels. In addition, a pillar-array fluid distributor made the blood velocity distribution even across the entire wedge-shaped microchannel which enhanced the anti-clogging effect of the wedge-shaped chamber. RBC would flow and randomly rotate through the micro-chamber when the height of the micro-chamber was larger than the size of RBC but if otherwise, RBC would be oriented flat due to their disk-like shape during sample processing. Interestingly, WBCs would also go through this microchip even the cut-off size of this chip is smaller than the diameter of WBC due to the size-space amplification by the wedge-shaped micro chamber. This design resulted in a capture efficiency of >93% for CTCs when processing the optimal blood volume of 2 mL at 200 μ L min⁻¹.

Recognising the potential of magnetic sorting, active microfluidic devices were demonstrated for the isolation of CTCs from whole blood (Table 5, entry 8).¹⁷ The magnetic sorter was fabricated by using medical grade cyclic olefin copolymer for the inertial separation array device. PDMS was annealed to a glass slide to avoid further deformations caused by baking or heating during fabrication of the magnetic sorter. Meanwhile, cyclic olefin copolymer (COC) was used for the main chip. COCs are inexpensive polymers derived from cyclic olefin monomers and ethene.¹⁸⁴ They are also transparent like PDMS except they have low elasticity and hydrophobic. Protein adsorption could be an issue on materials with hydrophobic surface but in this study, treatments to make the surface of the array device more hydrophilic were not applied. COC has the advantage of being a thermoplastic, hence devices can be made with high throughput by injection moulding. Separation relied solely on the device design rather than the material and occurred when the field gradient was intensified within the sorting channels using channels filled with "soft" (annealed) iron particles to act as magnetic micro-lenses. An increase in the applied magnetic field on inertially focused stream of cells efficiently depleted many leukocytes bound to magnetic beads, yielding 86% for CTCs and separating $\sim 99\%$ for leukocytes, erythrocytes and platelets respectively. This result was supported by cell counting and phase contrast microscopy experiments. Compared to the previous passive microfluidic devices for blood component separation, the high separation efficiencies here is specific for only one or few blood components.

5.4. Microfluidic devices for plasmapheresis

The presence of important biomarkers and proteins in blood plasma makes plasma a desirable body fluid for clinical analysis.¹⁸⁵ In order to achieve efficient separation for point-of-care applications, several different techniques were already applied such as geometrical obstructions,¹⁸⁶ cross-flow filtration¹⁸⁷ and bifurcation law, referred to as the Zweifach-Fung effect¹⁸⁸ or the process wherein shear is applied on cells driving them towards the centre of the channels of the micro-fluidic device forming a cell-free layer that can be captured at points where these channels divide (bifurcation points).¹⁶⁰

Instead of hydrodynamic pumps, the electro-osmotic flow (EOF) has also been used to drive the fluid flow for plasmapheresis in micro-channels¹⁸⁵ (Table 5, entry 9). The EOF is generated from the walls of the device when an electric field is applied. As the magnitude of the EOF correlates linearly with the electric field strength, fluidic separation mechanisms such as the Zweifach–Fung effect can be realised manipulating the electric field instead of a pump. By employing this separation mechanism, a yield of around 26% of blood plasma was collected from whole blood, with nearly 100% of the blood cells retained in the main channel. It should be noted that the volume of fresh human blood in the micro-channels was only $0.5 \ \mu L$ (diluted with 7.5 μL buffer).

Plasmapheresis was also realised using passive interlocked micropillar scaffolds fabricated from off-stoichiometry thiolenes (OSTE)¹⁸⁹ (Table 5, entry 10 and Fig. 4c). OSTE is a group of polymer synthesized *via* step polymerization of thiol and -ene groups.¹⁹⁰ By offsetting the stoichiometric ratios from 1:1, reactive groups in this polymer could be predicted making it easier for surface functionalization.¹⁹⁰ Separation in this device

happens when the blood sample clots upon material contact caused by deliberately adding an agglutination antibody to the material. The clots drastically minimize the surface area but allow for passage of the blood plasma through capillary action. When compared with previously established blood separation techniques such as centrifugation and membrane filtration (Fig. 4c, left), protein recovery rate improved from \sim 73% using membrane filtration¹⁹¹ to $\sim 82\%$ using this device. Effects of surface treatments using poly(ethylene glycol)methyl ether methacrylate (PEGMA) solution, hydroxyethylmethacrylate (HEMA) solution, bovine serum albumin (BSA) solution and oxygen plasma was also monitored and results showed that BSA treatment further improved the protein recovery rate to 91.7%. However, it should be accounted for that BSA is a protein itself and the result of measurement of protein recovery using BCA (bicinchoninic) protein assay in this study could be a false positive.

A passive, capillary flow-driven microfluidic device used oxygen plasma to induce a wettability gradient in the cylindrical well fabricated between the hydrophilic top and bottom channels of a PDMS microfluidic device¹⁶⁶ (Table 5, entry 11 and Fig. 4b). Upon introduction of blood sample within the hydrophilic device inlet, the difference in the Young-Laplace pressure induced a flow, with capillary action pulling the fluid front to the hydrophobic patch. The increasing contact angle at the hydrophobic patch decreased this force, significantly decreasing the fluid velocity. As the velocity decreased, the cells sedimented due to their higher density while the blood plasma continued to slowly rise, partially facilitated by its lower viscosity. Hence, the combination of gravity and capillarity underpins the plasma separation. When $< 10 \,\mu\text{L}$ of blood sample was injected in the device, 2 μL of plasma was obtained in 15 min with a separation efficiency of 99.9%. It is to be considered, however, that modification must be done for the device to be more applicable in continuous flow mode. The implementation of this approach aimed in this work towards diagnostics still faces challenges and further developments of the geometry of the system must be enabled to control the flow dynamics and facilitate continuous flow operation.

5.5. Conclusions for microfluidic-based apheresis

Microfluidic devices have great potential for use in blood apheresis, offering > 99% capture efficiencies for specific blood components. While parallel processing have enabled upscaling of microfluidic processing, microfluidic apheresis is currently more attractive in research since it can operate on very low blood volumes. Plasma separations, in particular, are highly

sought after for diagnostic purposes. While some microfluidic approaches have demonstrated volumetric throughputs nearing those of 'traditional' approaches (1 mL min⁻¹ for CIF vs. 50 mL min⁻¹ for centrifugation), significant technical advances in parallel processing are required to progress these technologies from research and diagnostics to the collection of blood products at a commercial scale. In terms of material development, other haemocompatible polymers aside from PDMS, COC and OSTE such as poly(methyl methacrylate) (PMMA) must be explored to fully tap the potential of these devices in blood component extraction while considering the polymer properties required for device fabrication. Surface modification such as incorporating zwitterionic polymers (e.g. carboxybetaine or sulfobetaine) or even grafting anticoagulants such as heparin on device channels could be helpful in avoiding fouling as in other apheresis techniques such as membrane filtration.

6. Perspectives

Apheresis techniques, which may be utilized for donor blood component collection, removal of disease-provoking elements and overexpressed blood components for blood cell isolation are critical to bio-products separation and pathogen removal. Advantages and limitations for each technique are summarized in Table 6. Centrifugation, membranes, adsorbents and microfluidic devices represent the most established and relevant approaches to this mean and were discussed in detail in this review.

The gaps of current apheresis technologies are primarily linked to yet incomplete or non-cost-effective removal or separation efficiency of bio-products, potential side effects to patients and damage induced to cells during the extraction processes. Alternative processes benefiting from advanced materials with tuned interactions with blood components represent a key avenue to limit biofouling of surfaces and membranes and prevent inopportune cell activation. The scalability of such devices is often limited and implementing simpler fabrication methods could lead to improvements towards more scalable technologies. The impact of blood coagulation proteins for blood apheresis are not prioritized thus preventing the massive application of these technologies in clinical settings.

Hence, future work must be directed on the interfacial chemistries between the blood and the material it interacts with to have a better understanding on the exact mechanism of contact, the functional groups that react and the configuration

Table 6 Advantages and limitations of current and emerging apheresis techniques

Apheresis technique	Advantages	Limitations
Centrifugal-based	Most utilized and established	High variabilities in separation time, low reproducibility and selectivity; strong mechanical shear stress inducing platelet activation
Membrane-based	Scalable and versatile	Low selectivity especially towards components of same size
Adsorbent-based	Highly selective	Low hemocompatibility of ligand materials
Microfluidic-based	Highly specific with capture efficiencies >99%; low processing volumes required	Fouling of microfluidic components

of the blood molecule that interacted with these functional groups. Future studies on these aspects are especially relevant now when there is an increasing trend towards incorporation of emerging materials whose properties are not yet fully understood, such as inorganic nanofillers incorporated with membrane and sorbents for enhanced mechanical property.

Biocompatible materials such as amphiphilic/zwitterionic polymers can also be explored as coating materials for these devices for enhanced haemocompatibility. Extensive haemocompatibility testing inclusive on the effects of the selected apheresis technology on coagulation proteins must be done as part of material development to aid in the translation of these technologies towards actual apheresis procedures. By comparing the separation efficiencies and percent recoveries of each technique, this review offers a selection of the possible ways of addressing the limitations in blood apheresis giving emphasis on the effects of surface modification methods and material design to enhance separation performance.

Author contributions

Christine Jurene O. Bacal: conceptualization, writing – original draft. Ludovic F. Dumee: conceptualization, supervision, writing – review and editing. Karen M. Dwyer: supervision, writing – review and editing. James W. Maina, Harshal H. Nandurkar, Yung Chang, Maryam T. Khaleel and Rosanne M. Guijt: writing – review and editing.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

L. F. D. acknowledges financial support from the Discovery Early Career Researcher Award (DECRA) from the Australian Research Council (ARC) (180100130) and from Khalifa University of Science and Technology under project RC2-2019-007.

References

- 1 J. Hardwick, ISBT Sci. Ser., 2008, 3, 148-176.
- 2 M. El Ekiaby, ISBT Sci. Ser., 2017, 12, 87-90.
- 3 C. Ronco and W. R. Clark, Nat. Rev. Nephrol., 2018, 14, 394-410.
- 4 W. R. Clark, F. Ferrari, G. La Manna and C. Ronco, *Contrib. Nephrol.*, 2017, **190**, 43–57.
- 5 G. M. Whitesides, Nature, 2006, 442, 368-373.
- 6 What is Apheresis? https://www.petermac.org/services/treat ment/haematological-treatments/apheresis/what-apheresis, (accessed October 13, 2021).
- 7 J. L. Winters, Hematology Am. Soc. Hematol. Educ. Program, 2012, 2012, 7–12.
- 8 N. Bose and H. Kanzariya, *Indian J. Anaesth.*, 2014, 58, 672–678.

- 9 M. E. Williams and R. A. Balogun, *Clin. J. Am. Soc. Nephrol.*, 2014, 9, 181–190.
- C. Klaus, B. Plaimauer, J.-D. Studt, F. Dorner, B. Lämmle, P. M. Mannucci and F. Scheiflinger, *Blood*, 2004, **103**, 4514.
- 11 E. Sumida, Y. Iwasaki, K. Akiyoshi and S. Kasugai, J. Pharmacol. Sci., 2006, 101, 91–97.
- 12 N. Worel, B. Mansouri Taleghani and E. Strasser, *Transfus. Med. Hemother.*, 2019, **46**, 394–406.
- 13 R. A. Ward, J. K. Leypoldt, W. R. Clark, C. Ronco, G. J. Mishkin and E. P. Paganini, *Semin. Dial.*, 2001, 14, 160–174.
- 14 S. Gosselin, D. N. Juurlink, J. T. Kielstein, M. Ghannoum, V. Lavergne, T. D. Nolin and R. S. Hoffman, *Clin. Toxicol.*, 2014, 52, 856–867.
- 15 A. M. Grunbaum, S. Kazim, M. Ghannoum, M.-A. Kallai-Sanfacon, R. Mangel, E. Villeneuve and S. Gosselin, *Clin. Toxicol.*, 2013, **51**, 270–271.
- 16 A. Urbansky, P. Ohlsson, A. Lenshof, F. Garofalo, S. Scheding and T. Laurell, *Sci. Rep.*, 2017, 7, 17161.
- A. Mishra, T. D. Dubash, J. F. Edd, M. K. Jewett, S. G. Garre, N. M. Karabacak, D. C. Rabe, B. R. Mutlu, J. R. Walsh, R. Kapur, S. L. Stott, S. Maheswaran, D. A. Haber and M. Toner, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 16839.
- 18 A. P. Sanchez, R. Cunard and D. M. Ward, J. Clin. Apher., 2013, 28, 20–29.
- 19 M. Kersaudy-Kerhoas and E. Sollier, *Lab Chip*, 2013, 13, 3323–3346.
- 20 S. C. Gifford, B. C. Strachan, H. Xia, E. Vörös, K. Torabian, T. A. Tomasino, G. D. Griffin, B. Lichtiger, F. M. Aung and S. S. Shevkoplyas, *PLoS One*, 2018, **13**, e0190827.
- 21 L. Wiegmann, D. A. De Zélicourt, O. Speer, A. Muller, J. S. Goede, B. Seifert and V. Kurtcuoglu, *Front. Physiol.*, 2017, 8, 731.
- 22 S. Fukuda and G. W. Schmid-Schönbein, *J. Leukoc. Biol.*, 2002, **72**, 133–139.
- 23 A. Seltsam, Front. Med., 2017, 4, 219.
- 24 G. de Sousa and J. Seghatchian, *Transfus. Apher. Sci.*, 2006, 34, 77–83.
- 25 B. Puppe and E. J. Kingdon, *Clin. Kidney J.*, 2014, 7, 201–205.
- 26 C. Hafer, P. Golla, M. Gericke, G. Eden, G. Beutel, J. J. Schmidt, B. M. W. Schmidt, S. De Reys and J. T. Kielstein, *Int. Urol. Nephrol.*, 2016, 48, 133–138.
- 27 M. E. Janssens and S. Wakelin, *Eur. Oncol. Haematol.*, 2018, 14, 105–109.
- 28 S. O. Catarino, R. O. Rodrigues, D. Pinho, J. M. Miranda, G. Minas and R. Lima, *Micromachines*, 2019, 10(9), 593.
- 29 J. Korsak and Z. Wańkowicz, Blood Purif., 2016, 41, 1-10.
- 30 D. M. Ward, J. Clin. Apher., 2011, 26, 230-238.
- 31 A. G. Perez, J. F. Lana, A. A. Rodrigues, A. C. Luzo, W. D. Belangero and M. H. Santana, *ISRN Hematol.*, 2014, 2014, 176060.
- J. Schwartz, A. Padmanabhan, N. Aqui, R. A. Balogun,
 L. Connelly-Smith, M. Delaney, N. M. Dunbar, V. Witt,
 Y. Wu and B. H. Shaz, *J. Clin. Apher.*, 2016, 31, 149–338.
- 33 J. Schwartz, J. L. Winters, A. Padmanabhan, R. A. Balogun,M. Delaney, M. L. Linenberger, Z. M. Szczepiorkowski,

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence

Dpen Access Article. Published on 18 October 2021. Downloaded on 5/26/2025 6:03:26 AM.

M. E. Williams, Y. Wu and B. H. Shaz, *J. Clin. Apher.*, 2013, **28**, 145–284.

- 34 Z. M. Szczepiorkowski, J. L. Winters, N. Bandarenko, H. C. Kim, M. L. Linenberger, M. B. Marques, R. Sarode, J. Schwartz, R. Weinstein and B. H. Shaz, *J. Clin. Apher.*, 2010, 25, 83–177.
- 35 J. E. Mancuso, A. Jayaraman and W. D. Ristenpart, *PLoS One*, 2018, **13**, e0203270.
- 36 D. M. Dohan Ehrenfest, N. R. Pinto, A. Pereda, P. Jiménez,
 M. D. Corso, B.-S. Kang, M. Nally, N. Lanata, H.-L. Wang and M. Quirynen, *Platelets*, 2018, 29, 171–184.
- 37 E. S. Lourenço, G. G. Alves, R. de Lima Barbosa, C. N. Spiegel, R. C. de Mello-Machado, S. Al-Maawi, S. Ghanaati and C. F. de Almeida Barros Mourão, *J. Biomed. Mater. Res., Part B*, 2021, **109**, 60–68.
- 38 X. H. Zheng, C. Cui, X. X. Zhou, Y. X. Zeng and W. H. Jia, *Chin. J. Cancer*, 2013, **32**, 667–672.
- 39 M. Lu, D. L. Lezzar, E. Vörös and S. S. Shevkoplyas, J. Blood Med., 2019, 10, 37.
- 40 R. Dhurat and M. Sukesh, J. Cutan. Aesthet. Surg., 2014, 7, 189–197.
- 41 D. Basu and R. Kulkarni, Indian J. Anaesth., 2014, 58, 529–537.
- 42 E. Hussein and A. Enein, Lab. Med., 2014, 45, 238-243.
- 43 L. Bongo, R. Bhatia and L. S. Lamb, Jr., *Blood*, 2018, 132, 5693.
- 44 P. Kes, M. E. Janssens, N. Bašić-Jukić and M. Kljak, *Transfusion*, 2016, **56**, 3065–3072.
- 45 M. Brambilla, L. Rossetti, C. Zara, P. Canzano, P. L. A. Giesen, E. Tremoli and M. Camera, *Platelets*, 2018, **29**, 406–414.
- 46 H. Fernandez-Munoz, C. Castilla-Llorente, E. M. Plaza, C. Martinez-Millan, I. Heras, P. Iniesta, M. L. Amigo, F. Ferrer-Marin, M. J. Candela, M. L. Lozano, V. Vicente and J. Rivera, *Blood Transfus.*, 2018, 16, 273–278.
- 47 A. K. Pulsfort, T. P. Wolter and N. Pallua, *Ann. Plast. Surg.*, 2011, 66, 292–295.
- 48 R. Landesberg, M. Roy and R. S. Glickman, J. Oral Maxillofac. Surg., 2000, 58, 297–300; discussion 300–291.
- 49 O. Bausset, L. Giraudo, J. Veran, J. Magalon, J. M. Coudreuse,
 G. Magalon, C. Dubois, N. Serratrice, F. Dignat-George and
 F. Sabatier, *Biores. Open Access*, 2012, 1, 115–123.
- 50 E. Anitua, J. J. Aguirre, J. Algorta, E. Ayerdi, A. I. Cabezas,
 G. Orive and I. Andia, *J. Biomed. Mater. Res., Part B*, 2008,
 84, 415–421.
- 51 M. Punzel, A. Kozlova, A. Quade, A. H. Schmidt and R. Smith, *Vox Sang.*, 2017, **112**, 586–594.
- 52 C. H. Jo, Y. H. Roh, J. E. Kim, S. Shin and K. S. Yoon, *J. Oral Implantol.*, 2013, **39**, 525–532.
- 53 J. Cadamuro, C. Mrazek, A. B. Leichtle, U. Kipman, T. K. Felder, H. Wiedemann, H. Oberkofler, G. M. Fiedler and E. Haschke-Becher, *Biochem. Med.*, 2018, 28, 010704.
- 54 D. M. Pegtel, K. Cosmopoulos, D. A. Thorley-Lawson, M. A. van Eijndhoven, E. S. Hopmans, J. L. Lindenberg, T. D. de Gruijl, T. Würdinger and J. M. Middeldorp, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 6328–6333.

- 55 G. Filardo, E. Kon, M. T. Pereira Ruiz, F. Vaccaro, R. Guitaldi, A. Di Martino, A. Cenacchi, P. M. Fornasari and M. Marcacci, *Knee Surg., Sports Traumatol., Arthrosc.*, 2012, 20, 2082–2091.
- 56 N. Tynngård, Transfus. Apher. Sci., 2009, 41, 97-104.
- 57 H. J. Gurland, M. J. Lysaght, W. Samtleben and B. Schmidt, *Int. J. Artif. Organs*, 1984, 7, 35–38.
- 58 C. Okafor, D. M. Ward, M. H. Mokrzycki, R. Weinstein, P. Clark and R. A. Balogun, *J. Clin. Apher.*, 2010, 25, 240–249.
- 59 A. Bruil, T. Beugeling, J. Feijen and W. G. van Aken, *Transfus. Med. Rev.*, 1995, **9**, 145–166.
- 60 A. Sueoka, Ther. Apher., 1998, 2, 78-86.
- 61 A. Sueoka, Ther. Apher., 1997, 1, 135-146.
- 62 T. Xiang, C. Cheng and C. Zhao, *J. Membr. Sep. Technol.*, 2014, 3, 162.
- 63 J. F. Hester, Doctor of Philosophy in Polymers Dissertation, Massachusetts Institute of Technology, 1993.
- 64 A. Higuchi, K. Sugiyama, B. O. Yoon, M. Sakurai, M. Hara, M. Sumita, S.-i. Sugawara and T. Shirai, *Biomaterials*, 2003, 24, 3235–3245.
- 65 L. Y. Ng, A. W. Mohammad, C. P. Leo and N. Hilal, *Desalination*, 2013, **308**, 15-33.
- 66 C.-C. Lien, P.-J. Chen, A. Venault, S.-H. Tang, Y. Fu, G. V. Dizon, P. Aimar and Y. Chang, *J. Membr. Sci.*, 2019, 584, 148–160.
- 67 P.-S. Liu, Q. Chen, S.-S. Wu, J. Shen and S.-C. Lin, *J. Membr. Sci.*, 2010, **350**, 387–394.
- 68 L. Zhu, F. Liu, X. Yu and L. Xue, ACS Appl. Mater. Interfaces, 2015, 7, 17748–17755.
- 69 S. Singh and A. Kumar, Biotechnol. J., 2009, 4, 1140-1151.
- 70 A. Bruil, H. A. Oosterom, I. Steneker, B. J. Al, T. Beugeling,
 W. G. van Aken and J. Feijen, *J. Biomed. Mater. Res.*, 1993,
 27, 1253–1268.
- 71 A. Bruil, W. G. Van Aken, T. Beugeling, J. Feijen, I. Steneker, J. G. Huisman and H. K. Prins, *J. Biomed. Mater. Res.*, 1991, 25, 1459–1480.
- 72 S. Teraoka, Y. Hayasaka, H. Shoji, M. Mineshima, T. Suzuki, Y. Sasaki, M. Sato, T. Hoshino, K. Era and T. Tojinbara, *et al.*, *ASAIO Trans.*, 1988, 34, 608–612.
- 73 R. R. Sharma and N. Marwaha, *Asian J. Transfus. Sci.*, 2010, 4, 3–8.
- 74 A. W. Neumann, D. R. Absolom, C. J. van Oss and W. Zingg, *Cell Biophys.*, 1979, 1, 79–92.
- 75 W. A. Zisman, *Contact Angle, Wettability, and Adhesion*, American Chemical Society, 1964, ch. 1, vol. 43, pp. 1–51.
- 76 J. Kjeldsen-Kragh and E. Golebiowska, *Vox Sang.*, 2002, 82, 127–130.
- 77 R. R. Gammon, S. A. Strayer, N. L. Avery and P. D. Mintz, *Ann. Clin. Lab. Sci.*, 2000, **30**, 195–199.
- 78 I. Steneker and J. Biewenga, Transfusion, 1991, 31, 40-46.
- 79 S. Dzik, Transfus. Med. Rev., 1993, 7, 65-77.
- 80 S. H. Ye, J. Watanabe and K. Ishihara, J. Biomater. Sci., Polym. Ed., 2004, 15, 981–1001.
- 81 M.-C. Sin, S.-H. Chen and Y. Chang, *Polym. J.*, 2014, 46, 436-443.

- 82 PuriBlood, http://www.puriblood.com/index.php?lang=en, (accessed March 13, 2021).
- 83 A. L. Lewis, R. N. Freeman, R. P. Redman, L. A. Tolhurst, L. C. Kirkwood, D. M. Grey and T. A. Vick, *J. Mater. Sci.: Mater. Med.*, 2003, 14, 39–45.
- 84 S. Clarke, M. C. Davies, C. J. Roberts, S. J. Tendler, P. M. Williams, V. O'Byrne, A. L. Lewis and J. Russell, *Langmuir*, 2000, 16, 5116–5122.
- 85 A. Higuchi, S.-i. Yamamiya, B. O. Yoon, M. Sakurai and M. Hara, J. Biomed. Mater. Res., Part A, 2004, 68A, 34–42.
- 86 Y.-W. Chen, A. Venault, J.-F. Jhong, H.-T. Ho, C.-C. Liu, R.-H. Lee, G.-H. Hsiue and Y. Chang, *J. Membr. Sci.*, 2017, 537, 209–219.
- 87 E. Gérard, E. Bessy, G. Hénard, T. Verpoort and J. Marchand-Brynaert, J. Biomed. Mater. Res., Part B, 2012, **100**, 1513–1523.
- 88 F. Sadeghi, A. Ajji and P. J. Carreau, J. Membr. Sci., 2007, 292, 62–71.
- 89 F. Sadeghi, A. Ajji and P. J. Carreau, *Polym. Eng. Sci.*, 2007, 47, 1170–1178.
- 90 Y. Cao, J. Liu, R. Zhong, Q. Yu and H. Wang, Artif. Cells, Blood Substitutes, 2012, 40, 317–325.
- 91 E. J. Kim, G.-D. Yeo, C.-M. Pai and I.-K. Kang, J. Biomed. Mater. Res., Part B, 2009, 90B, 849–856.
- 92 P. V. Mayuri, A. Bhatt, A. Sabaweeswaran and P. Ramesh, J. Biomater. Sci., Polym. Ed., 2020, 1–18, DOI: 10.1080/ 09205063.2020.1851559.
- 93 R. Hirano, K. Namazuda, J. Suemitsu, T. Harashima and N. Hirata, *Transfus. Apher. Sci.*, 2017, **56**, 649–653.
- 94 R. Vanholder, A. Argilés, U. Baurmeister, P. Brunet, W. Clark, G. Cohen, P. P. De Deyn, R. Deppisch, B. Descamps-Latscha, T. Henle, A. Jorres, Z. A. Massy, M. Rodriguez, B. Stegmayr, P. Stenvinkel and M. L. Wratten, *Int. J. Artif. Organs*, 2001, 24, 695–725.
- 95 M. Chmielewski, G. Cohen, A. Wiecek and J. Jesús Carrero, *Semin. Nephrol.*, 2014, **34**, 118–134.
- 96 C. Ronco and G. La, Manna, *Contrib. Nephrol.*, 2017, **190**, 124–133.
- 97 A. C. Yamashita, H. Masaki, E. Kobayashi and T. Sukegawa, *Hemodial. Int.*, 2015, **19**, S20–S25.
- 98 M. M. Amiji, J. Biomater. Sci., Polym. Ed., 1997, 8, 281-298.
- 99 M. Faria, C. Moreira, T. Eusébio, P. Brogueira and M. N. de Pinho, *Cellulose*, 2020, 27, 3847–3869.
- 100 N. Said, M. Nidzhom, H. Hasbullah, A. Ismail, P. Goh, M. Hafiz, M. H. Othman, S. Abdullah, S. Kadir, A. Kadir and F. Kamal, *Mal. J. Fund. Appl. Sci.*, 2020, 16, 1–5.
- 101 M. N. Z. Abidin, P. S. Goh, A. F. Ismail, M. H. D. Othman,
 H. Hasbullah, N. Said, S. H. S. A. Kadir, F. Kamal,
 M. S. Abdullah and B. C. Ng, *Mater. Sci. Eng.*, *C*, 2016, 68, 540–550.
- 102 P. G. Kerr and L. Huang, Nephrology, 2010, 15, 381-385.
- 103 A. K. Cheung, C. J. Parker, L. A. Wilcox and J. Janatova, *Kidney Int.*, 1990, **37**, 1055–1059.
- 104 Z. Zhang, S. Chen, Y. Chang and S. Jiang, J. Phys. Chem. B, 2006, 110, 10799–10804.
- 105 R. M. Hakim, D. T. Fearon, J. M. Lazarus and C. S. Perzanowski, *Kidney Int.*, 1984, **26**, 194–200.

- 106 J. C. Hutter, M. J. Kuehnert, R. R. Wallis, A. D. Lucas, S. Sen and W. R. Jarvis, *JAMA*, 2000, 283, 2128–2134.
- 107 M. E. Neumann, Nephrol. News Issues, 1996, 10(9), 11.
- 108 H. D. Humes, W. H. Fissell and K. Tiranathanagul, *Kidney* Int., 2006, 69, 1115–1119.
- 109 S. P. Adiga, C. Jin, L. A. Curtiss, N. A. Monteiro-Riviere and R. J. Narayan, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2009, 1, 568–581.
- 110 A. Gao, F. Liu and L. Xue, J. Membr. Sci., 2014, 452, 390-399.
- 111 M. Irfan, A. Idris, N. M. Yusof, N. F. M. Khairuddin and H. Akhmal, *J. Membr. Sci.*, 2014, **467**, 73–84.
- 112 J. R. Colvin, Can. J. Chem., 1952, 30, 831-834.
- 113 C. H. Trinh, D. P. Smith, A. P. Kalverda, S. E. V. Phillips and S. E. Radford, *Proc. Natl. Acad. Sci. U. S. A.*, 2002, **99**, 9771–9776.
- 114 F. Galli, S. Rovidati, L. Chiarantini, G. Campus, F. Canestrari and U. Buoncristiani, *Kidney Int.*, 1998, **54**, 580–589.
- 115 V. Sepe, M. Gregorini, T. Rampino, P. Esposito, R. Coppo, F. Galli and C. Libetta, *BMC Nephrol.*, 2019, **20**, 412.
- 116 M. Kiaii, M. Aritomi, M. Nagase, M. Farah and B. Jung, *J. Artif. Organs*, 2019, **22**, 307–315.
- 117 O. E. M. ter Beek, D. Pavlenko and D. Stamatialis, *J. Membr. Sci.*, 2020, **604**, 118068.
- 118 M. Tijink, J. Janssen, M. Timmer, J. Austen, Y. Aldenhoff, J. Kooman, L. Koole, J. Damoiseaux, R. van Oerle, Y. Henskens and D. Stamatialis, *J. Mater. Chem. B*, 2013, 1, 6066–6077.
- 119 Y. Liu, Y. Su, X. Zhao, Y. Li, R. Zhang and Z. Jiang, *J. Membr. Sci.*, 2015, **486**, 195–206.
- 120 M. Adeli, E. Mehdipour and M. Bavadi, *J. Appl. Polym. Sci.*, 2010, **116**, 2188–2196.
- 121 T. Xiang, C.-D. Luo, R. Wang, Z.-Y. Han, S.-D. Sun and C.-S. Zhao, *J. Membr. Sci.*, 2015, **476**, 234–242.
- 122 L. Wang, J. Wang, X. Gao, Z. Liang, B. Zhu, L. Zhu and Y. Xu, Polym. Chem., 2014, 5, 2836–2842.
- 123 K. Madhavan Nampoothiri, N. R. Nair and R. P. John, Bioresour. Technol., 2010, 101, 8493-8501.
- 124 J. K. Oh, Soft Matter, 2011, 7, 5096-5108.
- 125 M. M. Flanders, R. Crist and G. M. Rodgers, *Clin. Chem.*, 2003, **49**, 169–172.
- 126 M. Z. Fahmi, M. Wathoniyyah, M. Khasanah, Y. Rahardjo, S. Wafiroh and Abdulloh, *RSC Adv.*, 2018, **8**, 931–937.
- 127 M. Leeman, J. Choi, S. Hansson, M. U. Storm and L. Nilsson, *Anal. Bioanal. Chem.*, 2018, **410**, 4867–4873.
- 128 M.-M. Tu, J.-J. Xu and Y.-R. Qiu, RSC Adv., 2019, 9, 6254–6266.
- 129 N. J. Kaleekkal, A. Thanigaivelan, M. Durga, R. Girish, D. Rana, P. Soundararajan and D. Mohan, *Ind. Eng. Chem. Res.*, 2015, 54, 7899–7913.
- 130 M. Ghannoum, J. Bouchard, T. D. Nolin, G. Ouellet and D. M. Roberts, *Semin. Dial.*, 2014, 27, 350–361.
- 131 J. H. Salazar, Lab. Med., 2014, 45, e19-e20.
- 132 L. B. VanWagner and R. M. Green, *JAMA*, 2015, **313**, 516–517.
- 133 Q. Li, W. Zhao, H. Guo, J. Yang, J. Zhang, M. Liu, T. Xu,
 Y. Chen and L. Zhang, *ACS Appl. Mater. Interfaces*, 2020, 12, 25546–25556.

- 134 C. Tetta, R. Bellomo, A. Brendolan, P. Piccinni, A. Digito, M. Dan, M. Irone, G. Lonnemann, D. Moscato, J. Buades, G. La Greca and C. Ronco, *Kidney Int.*, 1999, 56, S15–S19.
- 135 G. La Greca, A. Brendolan, P. M. Ghezzi, R. De Smet, C. Tetta, R. Gervasio and C. Ronco, *Int. J. Artif. Organs*, 1998, **21**, 303–308.
- 136 K. Cao, C. P. Siepermann, M. Yang, A. M. Waas, N. A. Kotov, M. D. Thouless and E. M. Arruda, *Adv. Funct. Mater.*, 2013, 23, 2072–2080.
- 137 R.-L. Liu, Y. Wang, X.-L. Ge, P. Yu, H.-Q. Liu, M.-C. Wang, W. Lu and Q. Fu, *J. Biomater. Sci., Polym. Ed.*, 2017, **28**, 1444–1468.
- 138 S. E. Cowper, H. S. Robin, S. M. Steinberg, L. D. Su, S. Gupta and P. E. LeBoit, *Lancet*, 2000, 356, 1000–1001.
- 139 A. Sueoka, Ther. Apher., 1997, 1, 271-283.
- 140 D. Pavlenko, D. Giasafaki, G. Charalambopoulou, E. van Geffen, K. G. F. Gerritsen, T. Steriotis and D. Stamatialis, *Sci. Rep.*, 2017, 7, 14914.
- 141 C. A. Howell, S. R. Sandeman, Y. Zheng, S. V. Mikhalovsky, V. G. Nikolaev, L. A. Sakhno and E. A. Snezhkova, *Carbon*, 2016, **97**, 134–146.
- 142 Y. Yang, S. Yin, C. He, X. Wu, J. Yin, J. Zhang, L. Ma, W. Zhao, C. Cheng and C. Zhao, *J. Mater. Chem. B*, 2020, 8, 1960–1970.
- 143 R. S. Bedi, D. E. Beving, L. P. Zanello and Y. Yan, Acta Biomater., 2009, 5, 3265-3271.
- 144 Y. Yu, Chin. Sci. Bull., 2013, 58, 4357-4361.
- 145 X. Song, K. Wang, C.-Q. Tang, W.-W. Yang, W.-F. Zhao and C.-S. Zhao, *Biomacromolecules*, 2018, **19**, 1966–1978.
- 146 M. Eberhardson, P. Marits, M. Jones, P. Jones, P. Karlen, M. Karlsson, G. Cotton, K. Woznica, B. Maltman, H. Glise and O. Winqvist, *Clin. Immunol.*, 2013, **149**, 73–82.
- 147 J. H. Kang, M. Super, C. W. Yung, R. M. Cooper, K. Domansky, A. R. Graveline, T. Mammoto, J. B. Berthet, H. Tobin, M. J. Cartwright, A. L. Watters, M. Rottman, A. Waterhouse, A. Mammoto, N. Gamini, M. J. Rodas, A. Kole, A. Jiang, T. M. Valentin, A. Diaz, K. Takahashi and D. E. Ingber, *Nat. Med.*, 2014, **20**, 1211–1216.
- 148 J. Ciambella, D. C. Stanier and S. S. Rahatekar, *Composites, Part B*, 2017, **109**, 129–137.
- 149 N. M. Osmond, Adsorpt. Sci. Technol., 2000, 18, 529-539.
- 150 S. Chen, Y. Cao and J. Feng, ACS Appl. Mater. Interfaces, 2014, 6, 349–356.
- 151 A. Y. Rad, H. Yavuz, M. Kocakulak and A. Denizli, *Macromol. Biosci.*, 2003, **3**, 471–476.
- 152 W. Shi, Y. Shen, H. Jiang, C. Song, Y. Ma, J. Mu, B. Yang and D. Ge, *J. Membr. Sci.*, 2010, **349**, 333–340.
- 153 W. Yantasee, G. E. Fryxell, G. A. Porter, K. Pattamakomsan,V. Sukwarotwat, W. Chouyyok, V. Koonsiripaiboon, J. Xuand K. N. Raymond, *Nanomedicine*, 2010, 6, 1–8.
- 154 Y. Lin, S. K. Fiskum, W. Yantasee, H. Wu, S. V. Mattigod, E. Vorpagel, G. E. Fryxell, K. N. Raymond and J. Xu, *Environ. Sci. Technol.*, 2005, **39**, 1332–1337.
- 155 D. W. Whisenhunt, M. P. Neu, Z. Hou, J. Xu, D. C. Hoffman and K. N. Raymond, *Inorg. Chem.*, 1996, **35**, 4128–4136.
- 156 J. Chen, W. Han, R. Su, J. Chen, W. Zong, Y. Wang, W. Wang, G. Cheng, L. Ou and Y. Yu, *Artif. Cells, Nanomed.*, *Biotechnol.*, 2017, 45, 174–183.

- 157 L. Tan, R. He, Y. Li, Y. Liang, H. Li and Y. Tang, *J. Chromatogr. A*, 2016, **1459**, 1–8.
- 158 N. Wu, Z. Luo, Y. Ge, P. Guo, K. Du, W. Tang, W. Du, A. Zeng, C. Chang and Q. Fu, *J. Pharm. Anal.*, 2016, 6, 157–164.
- 159 T. Agishi, K. Takahashi, T. Yagisawa and K. Ota, *ASAIO Trans.*, 1991, 37, M496–M498.
- 160 M. E. Warkiani, L. Wu, A. K. Tay and J. Han, *Annu. Rev. Biomed. Eng.*, 2015, **17**, 1-34.
- 161 Z. T. Yu, K. M. Aw Yong and J. Fu, Small, 2014, 10, 1687–1703.
- 162 A. A. S. Bhagat, H. Bow, H. W. Hou, S. J. Tan, J. Han and C. T. Lim, *Med. Biol. Eng. Comput.*, 2010, 48, 999–1014.
- 163 H. W. Hou, A. A. S. Bhagat, W. C. Lee, S. Huang, J. Han and C. T. Lim, *Micromachines*, 2011, 2, 319–343.
- 164 J. C. McDonald and G. M. Whitesides, Acc. Chem. Res., 2002, 35, 491-499.
- 165 J. Zhou, A. Kulasinghe, A. Bogseth, K. O'Byrne, C. Punyadeera and I. Papautsky, *Microsyst. Nanoeng.*, 2019, 5, 8.
- 166 M. S. Maria, P. E. Rakesh, T. S. Chandra and A. K. Sen, *Sci. Rep.*, 2017, 7, 43457.
- 167 H. Xia, B. C. Strachan, S. C. Gifford and S. S. Shevkoplyas, *Sci. Rep.*, 2016, 6, 35943.
- 168 A. Papra, A. Bernard, D. Juncker, N. B. Larsen, B. Michel and E. Delamarche, *Langmuir*, 2001, **17**, 4090–4095.
- 169 K. M. Kovach, J. R. Capadona, A. S. Gupta and J. A. Potkay, J. Biomed. Mater. Res., Part A, 2014, 102, 4195–4205.
- 170 A. Mohd Noor, T. Masuda and F. Arai, *ROBOMECH J.*, 2020, 7, 5.
- 171 P. Sethu, A. Sin and M. Toner, Lab Chip, 2006, 6, 83-89.
- 172 X. Chen, D. F. Cui, C. C. Liu and H. Li, *Sens. Actuators, B*, 2008, **130**, 216–221.
- 173 X. Chen, D. F. Cui, C. C. Liu and H. Li, *Sens. Actuators, B*, 2008, **130**, 216–221.
- 174 H. Jang, M. R. Haq, J. Ju, Y. Kim, S.-M. Kim and J. Lim, *Micromachines*, 2017, **8**, 67.
- 175 P. Bacchin, M. Meireles and P. Aimar, *Desalination*, 2002, 145, 139–146.
- 176 Y. Lee and M. M. Clark, J. Membr. Sci., 1998, 149, 181-202.
- 177 B. Lombodorj, H. C. Tseng, H. Y. Chang, Y. W. Lu, N. Tumurpurev, C. W. Lee, B. Ganbat, R. G. Wu and F. G. Tseng, *Micromachines*, 2020, 11(3), 275.
- 178 S. Ookawara, M. Agrawal, D. Street and K. Ogawa, *Chem. Eng. Sci.*, 2007, **62**, 2454–2465.
- 179 P. Li, Z. S. Stratton, M. Dao, J. Ritz and T. J. Huang, *Lab Chip*, 2013, **13**, 602–609.
- 180 W. J. Allard, J. Matera, M. C. Miller, M. Repollet, M. C. Connelly, C. Rao, A. G. J. Tibbe, J. W. Uhr and L. W. M. M. Terstappen, *Clin. Cancer Res.*, 2004, **10**, 6897.
- 181 Y. Dong, A. M. Skelley, K. D. Merdek, K. M. Sprott, C. Jiang, W. E. Pierceall, J. Lin, M. Stocum, W. P. Carney and D. A. Smirnov, *J. Mol. Diagn.*, 2013, **15**, 149–157.
- 182 B. Hong and Y. Zu, *Theranostics*, 2013, 3, 377–394.
- 183 L. Wang, P. Balasubramanian, A. P. Chen, S. Kummar, Y. A. Evrard and R. J. Kinders, *Semin. Oncol.*, 2016, 43, 464–475.

- 184 P. S. Nunes, P. D. Ohlsson, O. Ordeig and J. P. Kutter, *Microfluid. Nanofluid.*, 2010, 9, 145–161.
- 185 H. Jiang, X. Weng, C. H. Chon, X. Wu and D. Li, *J. Micromech. Microeng.*, 2011, 21, 085019.
- 186 S. Choi, S. Song, C. Choi and J. K. Park, *Lab Chip*, 2007, 7, 1532–1538.
- 187 T. Tachi, N. Kaji, M. Tokeshi and Y. Baba, Anal. Chem., 2009, 81, 3194–3198.
- 188 S. Yang, B. Ji, A. Undar and J. D. Zahn, *ASAIO J.*, 2006, **52**, 698–704.
- 189 W. Guo, J. Hansson and W. van der Wijngaart, Anal. Chem., 2020, 92, 6194–6199.
- 190 M. Hillmering, G. Pardon, A. Vastesson, O. Supekar, C. F. Carlborg, B. D. Brandner, W. van der Wijngaart and T. Haraldsson, *Microsyst. Nanoeng.*, 2016, 2, 15043.
- 191 J. Hauser, G. Lenk, J. Hansson, O. Beck, G. Stemme and N. Roxhed, Anal. Chem., 2018, 90, 13393–13399.
- 192 Z.-Y. Tao, H. Xia, J. Cao and Q. Gao, Malar. J., 2011, 10, 251.
- C. Ronco, C. Crepaldi, A. Brendolan, L. Bragantini, V. d'Intini,
 P. Inguaggiato, M. Bonello, B. Krause, R. Deppisch and
 H. Goehl, *Nephrol. Dial. Transplant.*, 2003, 18, vii10–vii20.
- 194 R. M. Schaefer, W. Rautenberg, S. Neumann, A. Heidland and W. H. Hörl, *Clin. Nephrol.*, 1986, **26**(Suppl 1), S35–S38.
- 195 L. J. Langsdorf, L. G. Krankel and A. L. Zydney, *ASAIO J.*, 1993, **39**, M767–M772.
- 196 F. Aucella, M. Vigilante, G. Gatta, E. Grandone, D. Colaizzo, M. Margaglione, S. Modoni and C. Stallone, *Artif. Organs*, 2002, 26, 543–545.
- 197 N. Meert, S. Eloot, E. Schepers, H.-D. Lemke, A. Dhondt, G. Glorieux, M. Van Landschoot, M.-A. Waterloos and R. Vanholder, *Nephrol., Dial., Transplant.*, 2011, 26, 2624–2630.
- 198 J. K. Leypoldt, A. K. Cheung, L. Y. Agodoa, J. T. Daugirdas, T. Greene and P. R. Keshaviah, *Kidney Int.*, 1997, **51**, 2013–2017.
- 199 W. R. Clark, R. J. Hamburger and M. J. Lysaght, *Kidney Int.*, 1999, **56**, 2005–2015.
- 200 EXELTRA[™] Dialyzer, Single Use, 2003, p. K030974.
- 201 FX high-flux and FX low-flux dialyzers, https://www.fresenius medicalcare.asia/en/healthcare-professionals/hemodialysis/

dialyzers/fx-high-and-low-flux-dialyzers/, (accessed November 2, 2020).

- 202 S. Sibbel, A. Hunt, S. Laplante, W. Beck, M. Gellens and S. M. Brunelli, *ASAIO J.*, 2016, 62, 613–622.
- 203 Commonly used dialyzer specifications and substitution chart for visiting patients, http://www.bcrenalagency.ca/ resource-gallery/Documents/Commonly%20Used%20Dialy zer%20Specifications%20and%20Subs%20Chart.pdf, (accessed September 11, 2019).
- 204 P. Schuff-Werner and B. Holdt, *Artif. Organs*, 2002, 26, 117–123.
- 205 W. Samtleben, S. Bengsch, K.-S. Boos and D. Seide, *Artif. Organs*, 1998, **22**, 43–46.
- 206 N. Hirata, Y. Shizume, J. Shirokaze, J. Suemitsu, H. Yoshida and N. Yamawaki, *Ther. Apher. Dial.*, 2003, 7, 64–68.
- 207 M. Onishi, K. Shimura, Y. Seita and S. Yamashita, *Radiat. Phys. Chem.*, 1995, **46**, 219–223.
- 208 Q. Xia, Y. Yun, Q. Li, Z. Huang and Z. Liang, *Des. Monomers Polym.*, 2016, **20**, 201–209.
- 209 Filtryzer BG Hemodialyzer, https://www.toray-medical. com/en/products/dialysis/detail.html?key=0EB5426D0F D8A757492580D20022E798, (accessed December 30, 2020).
- 210 J. M. Campistol, J. V. Torregrosa, E. Ponz and B. Fenollosa, in *Polymethylmethacrylate. A Flexible Membrane for a Tailored Dialysis*, ed. C. Ronco, Karger, Basel, 1998, vol. 125, pp. 76–85.
- 211 I. Iizuka, Z. Yamazaki, Y. Fujimori, T. Takahama, F. Kanai, T. Wada, N. Inoue, T. Sonoda, T. Nogi and M. Kimura, *Ther. Apher.*, 2000, 4, 54–57.
- 212 D. Xie, L. Howard and R. Almousa, *J. Biomater. Appl.*, 2018, 33, 340–351.
- 213 S. Kim, B. Feinberg, R. Kant, B. Chui, K. Goldman, J. Park, W. Moses, C. Blaha, Z. Iqbal, C. Chow, N. Wright, W. H. Fissell, A. Zydney and S. Roy, *PLoS One*, 2016, **11**, e0159526.
- 214 N. J. Kaleekkal, D. Rana and D. Mohan, *RSC Adv.*, 2016, 6, 63156–63170.
- 215 K. Togo, M. Yamamoto, M. Imai, K. Akiyama and A. C. Yamashita, *Ren. Replace. Ther.*, 2018, 4, 29.